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robust regenerative ability. All vertebrate livers, for example, can make up for tissue mass loss (via surgical
excision of a portion of the liver) by replication of their differentiated cells within the remnant lobes. These
differentiated cells include parenchymal cells such as the hepatocytes and biliary epithelial cells (BECs) and
also non-parenchymal cells. Despite the proliferative capacity exhibited by hepatocytes, the mechanism for
how the liver regenerates after toxin injuries is debated. The liver is thought to utilize facultative stem cells
(FSCs) originating from the BECs, often referred to as "oval cells," for regeneration following toxin-based
injury. However, the notion that oval cells act as stem cells has been based largely on in vitro studies and
transplantation models; where lineage tracing has been employed, results have been conflicting. This thesis
work employs multiple genetic tools to lineage trace the origin and contribution of various cell populations to
liver regeneration in vivo. The findings reveal that contrary to stem cell-based models of regeneration, virtually
all new hepatocytes come from pre-existing hepatocytes with no evidence of BECs functioning as FSCs.
Instead, hepatocyte lineage tracing reveals in addition to replication, they can function as FSCs. Upon
perturbations including toxin injuries, they undergo a hepatocyte-to-BEC reprogramming process in vivo.
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phenomenon has rarely been observed in vivo without exogenous factors. However, a detailed in vivo analysis
reveals hepatocytes undergoing this cellular reprogramming process in a robust and step-wise manner
involving both morphological and transcriptional changes. This hepatocyte-to-BEC reprogramming requires
Notch signalling, similar to how the pathway functions in BEC-specification during liver development. These
results provide direct evidence that mammalian regeneration prompts extensive and dramatic changes in
cellular identity under various perturbations and thus can also serve as a cellular source for various diseases
and potentially for therapy involving BEC paucity and dysfunction.
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ABSTRACT 
 
CELLULAR MECHANISMS OF MAMMALIAN LIVER REGENERATION  
Kilangsungla Yanger 
Ben Z. Stanger 
  
 The liver is an essential organ that aids in metabolic processes, protein 
synthesis and detoxification of harmful substances. As the centre for detoxification, 
the liver is able to compensate for this routine damage with its robust regenerative 
ability. All vertebrate livers, for example, can make up for tissue mass loss (via 
surgical excision of a portion of the liver) by replication of their differentiated cells 
within the remnant lobes. These differentiated cells include parenchymal cells such 
as the hepatocytes and biliary epithelial cells (BECs) and also non-parenchymal 
cells. Despite the proliferative capacity exhibited by hepatocytes, the mechanism 
for how the liver regenerates after toxin injuries is debated. The liver is thought to 
utilize facultative stem cells (FSCs) originating from the BECs, often referred to as 
“oval cells,” for regeneration following toxin-based injury. However, the notion that 
oval cells act as stem cells has been based largely on in vitro studies and 
transplantation models; where lineage tracing has been employed, results have been 
conflicting. This thesis work employs multiple genetic tools to lineage trace the 
origin and contribution of various cell populations to liver regeneration in vivo. The 
findings reveal that contrary to stem cell-based models of regeneration, virtually all 
new hepatocytes come from pre-existing hepatocytes with no evidence of BECs 
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functioning as FSCs. Instead, hepatocyte lineage tracing reveals in addition to 
replication, they can function as FSCs. Upon perturbations including toxin injuries, 
they undergo a hepatocyte-to-BEC reprogramming process in vivo. Cellular 
reprogramming is the ability to interconvert distinct cell types with defined factors. 
This phenomenon has rarely been observed in vivo without exogenous factors. 
However, a detailed in vivo analysis reveals hepatocytes undergoing this cellular 
reprogramming process in a robust and step-wise manner involving both 
morphological and transcriptional changes. This hepatocyte-to-BEC reprogramming 
requires Notch signalling, similar to how the pathway functions in BEC-
specification during liver development. These results provide direct evidence that 
mammalian regeneration prompts extensive and dramatic changes in cellular 
identity under various perturbations and thus can also serve as a cellular source for 
various diseases and potentially for therapy involving BEC paucity and dysfunction.   
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 This chapter, containing excerpts with modifications, has been published: Yanger, K., Stanger, B.Z. 
Facultative stem cells in liver and pancreas: fact and fancy. Dev Dyn. 2011 Mar;240(3):521-9. 
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1.1 Overview of tissue regeneration and homeostasis 
1.1.1 Stem cells 
Stem cells are distinct from other mature cellular populations due to their unique 
ability to both self-renew (give rise to more stem cells) and differentiate into other cell 
types (Potten and Loeffler, 1990). The latter ability becomes more restricted as 
development progresses, resulting in a stem cell hierarchy based on the extent of potency 
(Slack, 2008). For instance, early on in development, cells from the inner cell mass of the 
blastocyst are considered to be pluripotent stem cells because they are able to give rise to 
all cell lineages except for extra embryonic tissues. With the onset of organogenesis later 
in development, stem cell potential becomes restricted as commitment to distinctive 
tissue-specific lineages occurs (Eckfeldt et al., 2005; Slack, 2008). An example of this is 
the male germline, in which the potential of self-renewing spermatogonial stem cells is 
limited to spermatogonia for the lifetime of a male organism (de Rooij, 2001). Adult 
tissues have two main mechanisms for replacing cells lost during routine cellular 
turnover. In some tissues, adult stem cells are the source of new cells throughout life, 
while other tissues are devoid of adult stem cells and maintain homeostasis through 
replication of existing cells. The skin, intestine, and blood are examples of tissues that 
continuously generate new cells from stem cells, while bone, kidney, and cartilage are 
examples of tissues in which stem cells play a limited, if any, role in normal organ 
homeostasis (Figure 1.1).  
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Figure 1.1 Mechanisms for maintaining homeostasis and regeneration 
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Figure 1.1 Two classical mechanisms for tissue homeostasis/regeneration involve 
differentiation of a stem/progenitor population (red box) or proliferation of differentiated 
cells (blue box). Hematopoietic stem cells have an apparently unlimited self-renewal 
capacity that enables them to continuously supply new blood cells, while cellular 
maintenance of the cartilage anlagen occurs by means of chondrocyte proliferation within 
the columnar region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
In contrast to normal tissue turnover, regeneration describes the process whereby 
new cells arise to replace those lost by injury. As with normal homeostasis, both stem 
cell-dependent and stem cell-independent mechanisms for regeneration are used by 
different tissues. However, under conditions of both homeostasis and injury, the relative   
balance between stem cell-dependent and – independent mechanisms of recovery has not 
been quantified. Thus, for most tissues, the relative degree to which stem cells contribute 
to tissue maintenance and regeneration remains undefined. The nature of the injury may 
also play a role in determining the recovery mechanism used by a given tissue. It has 
been postulated that following particular types of injury, a subset of differentiated cells 
can, in certain tissues, adopt a “stem cell-like” fate (Zipori, 2004). These cells have been 
termed facultative stem cells (FSCs) due to their ability to acquire multipotent qualities 
during conditions other than homeostasis, despite being initially unipotent (Figure 1.2). 
Such a potential blurs the stem cell-progeny paradigm that has been used by 
developmental biologists for decades. Thus, the biology of FSCs has relevance not only 
for tissue regeneration but could also serve to greatly inform our understanding of the 
multipotent or pluripotent state. Despite the potential importance of FSCs, the evidence 
supporting their existence is based mainly on in vitro models.  
1.1.2 Stem cell assays 
Historically, three major assays have been used to document stem cell activity: 1) 
clonogenic (in vitro) growth, 2) cellular transplantation, and 3) lineage tracing (Slack, 
2006). Each technique has both advantages and limitations. For example, clonogenic 
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growth can provide evidence of self-renewal and multilineage differentiation. Moreover, 
as an in vitro culture system, clonogenic growth can be technically straightforward.  
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Figure 1.2 Schematic of alternative cellular mechanisms of regeneration 
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Figure 1.2 As opposed to a unidirectional hierarchy resulting in mature cells through 
stem-cell differentiation or replication (black arrows), other mechanisms could account 
for tissue restoration (blue box expanded). These putative mechanisms include both the 
FSC model and other alternatives. (A) A mature, differentiated cell (green square) could 
dedifferentiate and acquire a progenitor identity (orange triangle), thus functioning as a 
FSC. (B) Mature cells could undergo reprogramming, which would allow them to 
interchange/transdifferentiate into other differentiated cells. Such a mechanism could be 
difficult to distinguish from the dedifferentiation–redifferentiation model in (A) unless 
the fates of the differentiated cells were followed with precision. (C) Finally, simple 
replication of existing differentiated cells could account for restoration of tissue mass. In 
this scenario, putative FSCs could simply be “bystanders” and not formally contribute to 
the regenerated tissue. 
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However, such assays do not necessarily indicate “stemness” in vivo. Moreover, 
growth assays assume that the progeny of the putative stem cell are “stable” in vitro. This 
latter point is critical, because the appearance of multiple cell types in a colony arising 
from a single cell is commonly taken as evidence of multipotency, yet this interpretation 
would be incorrect if differentiated cells placed in culture have the capacity to 
interconvert or “transdifferentiate.” Likewise, cell transplantation assays have been 
tremendously important in the identification and study of stem cells, particularly 
hematopoietic stem cells. However, transplantation assays can also be subject to 
confounding phenomena. One of the most important of these confounders is cell fusion, 
which can occur with many different types of cells and which can give a false impression 
regarding potency (Wagers and Weissman, 2004). 
The use of in vivo lineage tracing is a key technique for determining the origin of 
new cells. The most commonly used technique for lineage tracing in a mouse is Cre-Lox 
technology, which permits labelling to occur in a cell-type-specific manner. Additionally, 
a variant of the Cre recombinase fused to a mutated oestrogen receptor (Cre-ER
T2
) allows 
temporal control, labelling cells at a desired time point during development or adulthood. 
Through such genetic labelling, a cell’s subsequent fate and that of its progeny can be 
followed, as genetic lineage labelling constitutes a heritable marking. Such labelling of 
putative stem cell populations allows for stringent testing of stem cell properties of self-
renewal and pluripotency, and can provide insight into the cellular mechanisms of 
regeneration. However, Cre-Lox-based cell labelling uses the use of “tissue-specific” 
promoters to label cells, and thus the technique relies upon the specificity of such 
10 
 
promoters. Moreover, the inducible Cre-ER
T2
 variant requires tight regulation in order to 
avoid false labelling, particularly for FSC-studies. Hence, studies which use lineage 
labelling to determine whether stem cells contribute to homeostasis and/or regeneration 
are ultimately constrained by the specificity of the particular promoters and mouse strains 
used. 
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1.2 Modes of liver regeneration 
1.2.1 Cellular mechanisms of liver regeneration after partial hepatectomy 
For several decades, the liver has stood as the model organ for mammalian 
regenerative studies. The liver has multiple functions in normal physiology – including 
production of plasma proteins, synthesis of bile for fat emulsification, and detoxification, 
and liver failure is incompatible with life. The liver’s regenerative ability is apparent 
when, after removing two-thirds of its mass (partial hepatectomy, PHx), the remnant third 
is able to grow back to its original size and restore normal function (Higgins, 1931). The 
liver consists of several cellular components – two epithelial cell types (hepatocytes and 
biliary epithelial cells, or BECs) and several “non-parenchymal cell” (endothelial cells, 
macrophage-like “Kuppfer cells,” and fibroblasts) – organized into structures referred to 
as hepatic lobules. Hepatocytes comprise the vast majority of cells in the centre of the 
lobule, while BEC-lined bile ducts are found in regions known as portal tracts at the 
periphery of the lobule. Bile made by hepatocytes drains into the bile ducts through 
tubular structures known as the “Canals of Hering,” which constitutes a transitional zone 
between hepatocytes and BECs (Figure 1.3) 
The dominant cellular mechanism by which the liver regrows is proliferation  
(Figure 1.4 A) (Michalopoulos, 2007). In rats, normal liver mass is attained completely 
within 1 week while the mouse takes an additional week to do so. Studies using 
thymidine-H
3
 incorporation during various phases of PHx recovery in rodents have  
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Figure 1.3 Schematic view of FSCs location in the liver 
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Figure 1.3 Schematic depiction of a portal tract in the liver. Bile made by hepatocytes 
drains into the canalicular space and subsequently through the Canals of Hering into the 
bile duct. The precursors of oval cells in the liver have been proposed to reside within the 
Canals of Hering, the transitional zone between hepatocytes and biliary cells. HA, hepatic 
artery; PV, portal vein. 
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Figure 1.4 Mechanisms for maintaining homeostasis and regeneration in the liver 
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Figure 1.4 Following partial hepatectomy (PHx; A), differentiated liver cells undergo 
replication to make-up for the surgical loss of mass. In a toxin injury (B), a new cell type 
known as an “oval cell” is proposed to arise from BECs and function as a bipotent 
facultative stem cell (FSC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
 
demonstrated that cell replication following partial hepatectomy follows reproducible 
kinetics (Grisham, 1962). Hepatocytes constitute the first cell population to enter the cell   
cycle, followed by the biliary epithelial cells and then non-parenchymal cells 
(Michalopoulos and DeFrances, 1997; Taub, 2004). 
 In addition to cell proliferation, cellular hypertrophy has been shown to be 
another important regenerative mechanism dependent on the degree of injury and the 
state of the animal. Older mice have impaired liver regenerative capability compared to 
younger mice due to decreased proliferative ability (Iakova et al., 2003; Timchenko, 
2009). However, this defect in ageing female mice is reversed during pregnancy. Older, 
pregnant mice utilize cellular hypertrophy instead of cell proliferation, to recover at rates 
comparable to its younger control animals (Gielchinsky et al., 2010).  Additionally, the 
degree of the surgical excision has been shown to induce hypertrophy in addition to cell 
proliferation (Miyaoka et al., 2012).  
1.2.2 Molecular mechanisms of liver regeneration after partial hepatectomy 
The exact mechanism of how organs such as the liver ‘senses’ and controls its 
regenerative size is not known (Stanger, 2008). However, studies allude to both intrinsic 
and extrinsic signalling mechanisms being involved in PHx regeneration (Michalopoulos 
and DeFrances, 1997; Taub, 2004). For example, factors as diverse as interleukin-6 (IL-
6) and the bile acid receptor, FXR, have been reported to be important (Cressman et al., 
1996; Huang et al., 2006). Both IL-6 and FXR knockout mice after PHx display many 
anomalies during its regenerative process. Mortality rates during recovery are higher in 
IL-6 -/- and FXR -/- mice compared to their respective wildtype counterparts. Hepatocyte 
17 
 
replication appears to be compromised in both knockout animals as bromodeoxyuridine 
(BrdU) staining is greatly reduced in hepatocytes following injury. In IL-6 -/- animals 
this appears to be hepatocyte-specific as the nonparenchymal cells such as the endothelial 
and Kupffer cell proliferate normally and are comparable to wildtype livers (Cressman et 
al., 1996). This suggests that nonparenchymal cells do not need IL-6 for this process. 
However, mitogenic signals such as endothelial vascular growth factor (VEGF) are 
secreted by hepatocytes for sinusoidal endothelial cell proliferation in PHx recovery, thus 
revealing the existence of a paracrine relationship (Shimizu et al., 2001).  
Many IL-6 -/- animals that recover after a PHx are jaundiced, have smaller and 
highly necrotic livers (Cressman et al., 1996). However, despite the IL-6 knockout, not 
all animals display these pockets of necrosis, potentially indicating the ability of the liver 
to compensate for this mutation. Indeed, wildtype hepatocytes have been shown to be 
able to clonally repopulate ~95% of the liver in urokinase-type plasminogen activator 
(uPA) transgenic mice (Sandgren et al., 1991). The replicative ability of hepatocytes has 
been displayed in serial transplantation studies, with calculations suggesting that a single 
hepatocyte is competent to give rise to many entire livers (Overturf et al., 1997).  
Transplantation assays allude to species-specific intrinsic regenerative 
mechanisms. For example, rat hepatocytes transplanted into mice livers that undergo a 
PHx exhibit entry into the cell cycle sooner than mouse hepatocytes. Despite being in a 
mouse-specific cellular milieu, the rat hepatocytes label with BrdU within 24 hours like 
they do normally and not later at 32 hours like the mouse hepatocytes (Weglarz and 
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Sandgren, 2000). Thus hepatocytes display a certain degree of species-specific cell 
autonomous features.  
1.2.3 Liver regeneration in toxin injury and origins of FSC model  
Despite the robust regenerative capacity of hepatocytes, it is widely believed that 
an alternative mechanism for adult regeneration, involving FSCs, is used following 
certain types of liver injury (Figure 1.3). This hypothesis initially emerged from studies 
in which the rat liver was forced to regenerate following exposure to one of several 
hepatotoxic carcinogens. In rats, it is believed these cells emerge as a result of impaired 
hepatocyte replication, although in the mouse, counterparts of these cells still appear in 
injured livers despite the ability of hepatocytes to proliferate (Ghoshal et al., 1983; Wang 
et al., 2003a). Under such conditions, a distinctive histological picture was noted, 
characterized by the emergence of a heterogeneous population of small oval-shaped cells 
with biliary properties (Farber, 1956). Subsequent work revealed that cells with a similar 
appearance are observed in many or most models of hepatocarcinogenesis or toxin-
induced injury (Lee et al., 2006; Roskams et al., 2003). These cells have been referred to 
by many different names including “ductular hepatocytes,” “intermediate hepatobiliary 
cells,” “atypical ductular proliferation,” or more commonly as “oval cells,” a term 
adopted from rodent studies (Factor et al., 1994; Gerber et al., 1983; Preisegger et al., 
1999; Zhou et al., 2007). They are characterized by small size, an ovoid nucleus, scant 
cytoplasm, poorly defined lumen, and lack of basement membranes (Factor et al., 1994; 
Gerber et al., 1983; Preisegger et al., 1999). Although debated, oval cells are proposed to 
emerge from the BECs in the Canals of Hering (Dorrell and Grompe, 2005; Fausto and 
19 
 
Campbell, 2003) (Figure 1.2) and, after injury, are thought to interpose themselves 
between biliary ductules and so-called “intermediate hepatocytes,” cells which share 
characteristics of both hepatocytes and oval cells (Factor et al., 1994; Preisegger et al., 
1999). This transitory morphology and proximity of the hepatocytes to oval cells has 
been taken as evidence of differentiation of the latter into the former, and static 
visualization by light microscopy is consistent with that view (Factor et al., 1994).  
1.2.4 In vitro experiments of FSC  
Several in vitro experiments performed in the 1980s demonstrated that cultured 
oval cells could adopt either hepatocyte or biliary features depending upon culture 
conditions, a phenomenon similar to that observed with culture of fetal rat hepatocytes 
that have bona fide multipotent properties (Germain et al., 1988a; Germain et al., 1985; 
Germain et al., 1988b). Similar results were obtained by investigators who derived cell 
lines with “oval” cell properties (Tsao et al., 1984) and subsequently many such lines 
have been derived which are referred to as “liver epithelial cell lines” or BMEL cells 
(“bipotential mouse embryonic liver”; (Strick-Marchand et al., 2004)). Nevertheless, 
there is conflicting lineage-based evidence to confirm such ontological conclusions about 
bipotentiality (Taub, 2004; Zaret and Grompe, 2008). One of the difficulties in doing 
lineage tracing experiments with oval cells has been the lack of oval cell-specific 
markers. Although several features that distinguish oval cells from normal biliary 
epithelial cells have been reported (e.g.(Sirica et al., 1990)), immunohistologic studies 
with antibodies are unable to distinguish between oval cells and BECs (Fausto and 
Campbell, 2003). Importantly, oval cells represent a heterogeneous population that 
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includes both epithelial-derived and bone marrow-derived cells that exhibit distinct cell 
surface profiles (Dorrell et al., 2008; Okabe et al., 2009). Recent efforts have sought to 
identify novel cell-surface antibodies that are oval cell specific (Dorrell et al., 2008), but 
these and other studies have often yielded antibodies that also recognize normal BECs. 
Thus, at least based on immunostaining data, there is no compelling evidence that oval 
cells represent a distinct cell type that is not present in the normal liver. 
1.2.5 Cell transplantation assays of FSC  
Cell transplantation experiments provide another line of evidence in support of 
oval cell bipotentiality. Again, because of a paucity of markers, oval cell isolation for 
initial studies have been forced to rely on cell fractionation techniques based on the 
smaller size of the oval cell (Fausto and Campbell, 2003). Cells isolated in this fashion, 
although contaminated with others cells such as hematopoietic cells, can rescue 
fumarylacetoacetate hydrolase mutant (FAH-/-) mice as effectively as hepatocytes, 
indicating that this population has robust hepatocyte differentiation-reconstitution 
capacity (Wang et al., 2003a). This study, however, does not specifically address whether 
new biliary cells emerged from these transplanted cells. Lineage tracing studies also give 
support to the notion that nonhepatocytes can give rise to hepatocytes during toxin-
mediated injury (Pichard et al., 2009). 
During the late 1990s, it was proposed that bone marrow (BM) derived cells 
might serve as facultative stem cells for liver regeneration and might even give rise to 
oval cells (Petersen et al., 1999). However, subsequent studies showed that this 
phenomenon was not due to transdifferentiation but cell fusion (Alvarez-Dolado et al., 
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2003; Wang et al., 2003b). This fusion was shown by transplanting Cre-expressing bone 
marrow cells to R26-LacZ reporter mice that require Cre recombination for LacZ 
expression. β-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) staining occurs in cells 
positive for LacZ. Hepatocytes in the liver were found to be β-Gal positive, signifying a 
recombination event with the fusion of a Cre-expressing and a R26-LacZ cell (Alvarez-
Dolado et al., 2003). Another study using female donors and male recipients confirmed 
cell fusion using karyotype analysis. Hepatocytes in transplanted male animals were 
found to consist of XXXY and XXXXYY  karyotypes (Wang et al., 2003b) . These cell 
fusion events occur with low frequency, but in the appropriate selective environment, 
hepatocytes generated by a fusion event are capable of significant expansion through 
simple replication. Thus, while there may be a small degree of cell-fusion occurring with 
bone marrow cells, the frequency and extent of this phenomenon is considered to be of 
non-physiological significance (Oertel and Shafritz, 2008; Wang et al., 2003a). 
1.2.6 In vivo studies of FSC  
Electron microscopy studies reveal that following injury with the hepatotoxin 
Dipin, a series of “transitional” cells – cells with ultrastructural features of both ductular 
cells and hepatocytes – were found (Factor et al., 1994). These cells were larger than oval 
cells but smaller than hepatocytes, had variable nucleocytoplasmic rations, mitochondrial 
content, and glycogen rosettes (Factor et al., 1994). Thus, at the ultrastructural level, oval 
cells do seem to comprise a heterogeneous population of cells, with some exhibiting 
intermediate features “between” hepatocytes and BECs. 
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One marker used for lineage tracing study which supports the view that oval cells 
can exhibit bipotentiality was the Foxl1 marker, in which Foxl1-Cre mice were used to 
label putative progenitor cells (Sackett et al., 2009). Foxl1 is a mesenchymal marker, and 
mice in which the Foxl1 lineage was labeled (using a lacZ lineage ‘reporter’) exhibited β-
Gal activity in both hepatocytes and biliary cells following injury. This result does not 
distinguish between the possibility that a single bipotential progenitor cell was labeled vs. 
the alternative explanation that hepatocytes and biliary cells both independently activated 
the Foxl1 promoter (leading to cell labelling) upon injury, and additional experiments 
will be needed to resolve these issues. 
More recent studies utilizing inducible-Cre promoters have been used to 
lineage trace oval cells in vivo, though they have also led to disparate results 
(Friedman and Kaestner, 2011). For instance, studies utilizing similar Sox9-CreER 
strains result in opposing findings, with one favouring a stem role for Sox9
+
 BECs 
(Furuyama et al., 2011) while another did not find evidence of this (Carpentier et 
al., 2011). Cre-based labelling employing osteopontin (Opn) or Lgr5- inducible 
drivers have supported the idea of bipotent oval cells (Espanol-Suner et al., 2012; 
Huch et al., 2013). In both cases, inheritance of the label was found in hepatocytes, 
though in low amounts. However, other in vivo lineage tracing studies come to 
opposing conclusions, of which has been shown by other studies (Malato et al., 
2011) and my own, which will be discussed in this work. 
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1.2.7 Summary 
In summary, the liver is believed to have two mechanisms for regeneration 
depending upon the mechanism of injury (Figure 1.3). Following partial extirpation 
(PHx), remaining hepatocytes re-enter the cell cycle, undergoing one or two rounds of 
cell division resulting in a complete recovery of liver size. This cellular mechanism for 
regrowth is well established, and several of the signalling pathways that mediate this 
growth response have been identified (although the identity of the size “sensor” that 
informs the liver that regrowth is needed remains elusive). By contrast, injury with 
hepatotoxins results in the emergence of numerous small cells – most commonly referred 
to as oval cells – that arise in the portal tracts and make their way into the lobules. Cell 
transplantation studies and in vitro differentiation experiments suggest that these cells 
exhibit multipotency under these experimental conditions, but in vivo studies exhibit 
opposing views and thus definitive evidence that these cells act as multipotent progenitor 
cells remains deficient. Likewise, although these cells are commonly believed to arise 
from BECs within the Canals of Hering, their precise origins also remain uncertain. Such 
a cell type holds much promise for regenerative medicine in light of the acute shortage of 
transplantable donor livers (Karp, 2009) .  
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2 ADULT HEPATOCYTES ARE GENERATED BY SELF-DUPLICATION 
RATHER THAN STEM-CELL DIFFERENTIATION 
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2.1 Introduction  
 Tissue homeostasis in adult tissues is maintained via replication of 
differentiated cells or stem cell differentiation. In addition to these well-established 
paradigms, it has been proposed that select tissues contain a population of so-called 
“facultative stem cells.” By definition, facultative stem cells (FSC) lack stem cell 
activity during normal tissue turnover but are thought to be recruited during specific 
types of injury to behave like stem cells (Yanger and Stanger, 2011). The 
mammalian liver is widely viewed as a paradigm for regeneration via FSC-
mediated recovery. In response to various disease states and toxin-induced injuries, 
rodents and humans exhibit an accumulation of atypical ductal cells (ADCs) – 
commonly referred to as “oval cells” – within the liver parenchyma (Farber, 1956; 
Popper et al., 1957). ADCs have a ductal morphology, but their arrangement into an 
intricate anastomosing configuration that extends into the hepatic lobule gives them 
a histologic appearance that is distinct from that of normal biliary epithelial cells 
(BECs) (Desmet, 1985). ADCs are thought to arise from BECs within the Canals of 
Hering, structures that reside at the interface of the intrahepatic bile ducts and 
hepatocyte-lined canaliculi (Factor et al., 1994; Preisegger et al., 1999).  
 Based on in vitro studies, ultrastructural analysis and cell transplantation 
assays, ADCs have been proposed to function as bipotent FSCs, giving rise to both 
hepatocytes and BECs, during toxin-mediated liver injury, although this issue is 
controversial (Espanol-Suner et al., 2012; Fausto and Campbell, 2003; Friedman 
and Kaestner, 2011; Furuyama et al., 2011; Huch et al., 2013; Malato et al., 2011; 
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Zaret and Grompe, 2008). Furthermore, adult hepatocytes exhibit significant 
plasticity in vivo (Michalopoulos et al., 2005; Yanger et al., 2013), a phenomenon 
that may give the appearance of stem cell-mediated differentiation. In order to 
obtain evidence for liver stem cell activity in vivo, I specifically labelled distinctive 
cell populations in the liver – BECs and hepatocytes, and transit amplifying cells 
(the results of the latter done in collaboration will be discussed briefly) – using both 
direct genetic and unbiased nucleoside analogue-based lineage labelling tools under 
multiple ADC-inducing injury conditions. Our results suggest that hepatocytes, not 
stem cells, serve as the major source for renewal and regeneration in the liver. 
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2.2 Results 
2.2.1 ADC-inducing injuries 
The liver was injured in several ways to induce ADCs  including chow 
containing DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine) (Wang et al., 2003a), 
CDE diet (choline-deficient ethionine supplemented) (Carpentier et al., 2011), CCl4 
administration (carbon tetrachloride) (Malato et al., 2011), and ANIT (alpha-
naphthyl-isothiocyanate) (Faa et al., 1998), all of which act as hepatotoxins that has 
been used extensively for studies of ADC/oval cell biology (henceforth, the term 
ADCs will be used to refer to cells with an “oval cell” or “progenitor” phenotype). 
As expected, I observed the emergence of numerous ADCs within 2 weeks of DDC, 
ANIT and CCl4 treatment and within 4 days of CDE treatment. ADCs first arose in 
the portal regions and expressed both “classical” ADC markers (e.g. A6 and 
KRT19) as well as a number of newly-generated ADC markers  (Figure 2.1; 
(Dorrell et al., 2008; Wang et al., 2003a)). Based on pilot experiments, I adopted a 
regimen whereby animals received a normal diet for 3-5 weeks following DDC 
treatment and 2 weeks after CDE and ANIT diet, a protocol that resulted in a return 
to near-normal liver histology. All hepatotoxins were associated with substantial 
hepatocyte death as assessed by cleaved caspase 3 staining and proliferation with 
BrdU incorporation (Figure 2.2). Thus, all treatment regiments were associated with 
a robust ADC response during which a substantial fraction of hepatocytes 
underwent turnover. 
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Figure 2.1 Example of liver injury resulting in an atypical ductal cell response and 
cessation after recovery 
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Figure 2.1 (A) DDC treatment is associated with an expansion of liver cells 
expressing a variety of oval cell/ADC markers compared to control livers. Several 
markers of “non-parenchymal” cells (2F3 and 3C7) were expressed only following 
DDC treatment, whereas all epithelial-specific markers (A6, 1D11, Trop2, and 
KRT19) were expressed in both normal ducts and oval cells/ADCs. (B) The injury-
recovery protocol (2 weeks of DDC followed by 5 weeks of normal diet) is 
associated with an expansion and regression of the KRT19
+
1D11
+
 population. 
Scale: white bar=50μm; black bar=100μm; yellow bar=50μm. 
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Figure 2.2 Example of toxin injury associated with significant cellular turnover 
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 Figure 2.2 (A) Administration of a DDC diet leads to an ADC response, characterized 
by the expansion of small BEC-like cells from the peri-portal region into the lobule. 
Animals given BrdU in the drinking water for two weeks with either regular chow 
(Normal) or in combination with a DDC-containing diet (DDC) exhibit marked 
proliferation of both BECs, marked by CK19 (B, arrowheads), and hepatocytes, marked 
by HNF4α (C, arrowheads). (D) DDC treatment also leads to a significant increase in 
hepatocyte cell death, as detected by staining for cleaved caspase-3. Scale bar=50µm. 
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2.2.2 Lineage tracing biliary epithelial cells in vivo 
  It has been proposed that BECs residing within the Canals of Hering serve 
as precursors of liver progenitor cells (Figure 2.3 (Factor et al., 1994; Wang et al., 
2003a)). Therefore, I crossed inducible cytokeratin-19 promoter (Krt19) CreER 
knock-in mice (Means et al., 2008) to Rosa26
YFP
 reporter mice (Srinivas et al., 
2001) to label cells from the BEC lineage – prior to injury – to look for evidence 
that these cells could give rise to hepatocytes (Figure 2.3). Bigenic Krt19-
CreER/R26
YFP
 mice animals were given tamoxifen (TM), resulting in pulse 
labelling of BECs with an efficiency of 36.2±8.7% (Figure 2.4 A, top, n=4), 
including cells within the Canals of Hering (Figure 2.4 A, side panels). Importantly, 
labelling was completely restricted to BECs, as previously reported (Figure 2.4 A; 
(Scholten et al., 2010)).  
 I then tested whether labelled BECs give rise to hepatocytes under injury or 
homeostatic conditions. 6-8 week old bigenic animals were given TM and after a 
washout period were subjected to either an injury-recovery protocol with various 
ADC-inducing injury models including DDC, CDE diet, CCl4 administration, and 
ANIT or left uninjured. Under all injury-recovery circumstances, YFP
+
 cells co-
stained for biliary markers but not hepatocyte markers, indicating that labelled 
BECs did not give rise to hepatocytes (Figure 2.4 B and data not shown; DDC:1191 
cells counted, n=3; CDE: 1157 counted, n=3). I next determined whether BECs 
might generate hepatocytes over longer periods of time, as has been previously  
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Figure 2.3 Mechanisms for lineage tracing biliary epithelial cells 
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Figure 2.3 Schematic view of BEC labelling using Krt19-CreER; R26
YFP
mice. 
Cells are marked in a mosaic fashion upon TM injection (“Pulse”), and the ability 
of labelled BECs to give rise to hepatocytes is assessed following injury and 
recovery /under homeostatic conditions (“Chase”). 
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Figure 2.4 BECs lack detectable progenitor cell activity in vivo 
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Figure 2.4 (A) YFP-labelling at “pulse.” Labelling occurs exclusively in BECs - 
encompassed BECs lining ducts (arrowhead) as well as BECs within the Canal of 
Hering (side panels). (B) Following injury-recovery, a similar pattern and degree of 
labelling is observed after the chase; no YFP label is observed in hepatocytes 
(“Chase” – DDC and CDE). Unperturbed livers studied after 9 months do not show 
any hepatocytes bearing the YFP label (“Chase” = 9 months). The images shown 
are representative of multiple experiments (Pulse: n=7; DDC:  n=8; CDE: n=3; 9 
months chase group: n=5). CV, central vein; PV, portal vein; HA, hepatic artery; 
Scale bar=50µm.  
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reported for Sox9
+
 BECs (Furuyama et al., 2011). Following  a 9 month labelling 
“chase,” all YFP
+
 cells  expressed biliary markers (1154 counted; n=4) but not 
hepatocyte markers or morphology (Figure 2.4 B, 4773 counted). Hence, KRT19-
expressing BECs do not appear to give rise to hepatocytes following injury or 
during normal liver turnover.  
2.2.3 Lineage tracing atypical ductal cells in vivo 
 It is possible that KRT19
+
ADCs arise from a unique cell population that is 
not labelled in the quiescent state. To this end, I administered TM to Krt19-
CreER/R26
YFP
 animals during the second-half of DDC injury, thus labelling newly-
formed ADCs (Figure 2.5 A). Injury alone (in the absence of TM) did not induce 
recombination of the reporter allele, an important control to verify the stringency of 
the inducible promoter (Figure 2.5 B). TM administration during DDC treatment 
resulted in YFP labelling of 22.7±4.6% of K19
+
 cells, including A6
+
 ADCs 
(“Pulse”; n=3; Figure 2.5 C). Labelling encompassed cells within large mature-
appearing ductal structures as well as isolated ductal cells that penetrated the lobule. 
Labelling was highly specific for ADCs, as all labelled cells (1010 counted, n=6) 
exhibited a biliary morphology and stained positive for ADC/biliary markers, but 
lacked a hepatocyte morphology and were negative for HNF4α (Figure 2.5 C).  
  Following a 3-week recovery (“Chase”), YFP
+
 cells were readily detected in 
the livers of Krt19-CreER/R26
YFP
 mice (Figure 2.5 D). Consistent with our results 
from BEC labelling prior to injury, YFP expression was never observed in cells  
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Figure 2.5 ADCs do not give rise to hepatocytes 
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Figure 2.5 (A) Schematic view of lineage tracing of ADCs. An idealized 
hexagonally-shaped lobule is shown on the left. A blow-up of one portal tract 
illustrates the interface between biliary epithelial cells (BECs; blue) and 
hepatocytes (crimson). Treatment of animals with the toxin DDC (“Injury”) leads to 
the emergence of ADCs in the lobule (blue cells mingled with hepatocytes). 
Lineage labelling (“Pulse”) results in the heritable marking of ADCs (green) but not 
hepatocytes, whose progeny can be followed after recovery (2 weeks DDC 
followed by 5 weeks normal chow; “Chase”). (B) DDC-treated Krt19-CreER; 
R26
YFP
 mice do not exhibit YFP expression in the absence of TM. (C) The Krt19-
CreER transgene permits specific labelling of KRT19
+
 and A6
+
 ADCs after DDC 
treatment. No hepatocytes were labelled during the pulse. (D) Following recovery 
(“Chase”), no label-bearing hepatocytes were observed. White bar=50µm 
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with a hepatocyte morphology or HNF4α expression (2474 counted; n=5). YFP
+
 
cells in the recovery group resembled normal BECs, exhibiting a biliary 
morphology and staining with biliary markers (Figure 2.5 D). As some 
stem/progenitor cell populations undergo replication rates that differ from that of  
surrounding cells (Blanpain et al., 2007), I  ensured there was equal YFP labelling 
of proliferating and non-proliferating ADCs using Ki-67 (Figure 2.6). These results 
indicate that ADCs labelled during injury do not give rise to hepatocytes. Taken 
together, the results reveal that neither ADCs nor BECs (their presumptive cell of 
origin), give rise to hepatocytes under homeostatic conditions or after toxin-
mediated injury. 
2.2.4 Determining hepatocyte neogenesis in vivo 
 These experiments do not rule out the possibility that hepatocytes arise from 
progenitor cells that were not marked by the Krt19-CreER labelling approach 
(including “marker negative” cells). To test this possibility, I labelled differentiated 
hepatocytes and determined the contribution of “non-hepatocytes” to recovery 
following injury (Figure 2.7 A). The rationale for the approach follows from the 
expectation that unlabelled stem cells contributing to liver regeneration would give 
rise to unlabelled progeny, resulting in decreased hepatocyte-labelling index (Figure 
2.7 B (i)). Alternatively, if new hepatocytes are derived solely from existing 
hepatocytes, then the hepatocyte labelling index would remain unchanged (Figure 
2.7 B (ii)). This method has been used as a general means of determining the degree  
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Figure 2.6 TM administration to Krt19-CreER/R26YFP mice results in equal 
labelling of proliferating and non-proliferating ADCs 
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Figure 2.6 I sought to ensure that TM administration to Krt19-CreER/R26
YFP
 mice 
resulted in equal labelling of proliferating and non-proliferating ADCs. Hence, I used Ki-
67 to compare the fraction of proliferating cells in (A) both YFP
-
 (arrows) and YFP
+
 
(arrowheads) ADCs with (B) with equal frequency of Ki-67
+
 cells comprising 
approximately 8% in both populations (mean ±SD). Yellow bar=10 µm 
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Figure 2.7 A pulse-chase system for determining the origin of regenerating 
hepatocytes 
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Figure 2.7 (A) Schematic view of lineage tracing hepatocytes. Lineage labelling 
(“Pulse”) results in the heritable marking of hepatocytes (green) but not BECs. (B) 
Predictions from different models of liver regeneration. After injury and recovery 
(“Chase”), stem cell-based repair would result in a decrease in the hepatocyte 
labelling index (i), while hepatocyte-mediated recovery would result in no change 
(ii).  
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to which putative stem/progenitor cells contribute to tissue regeneration when 
markers of such cells are lacking (Dor et al., 2004).  
Hepatocyte labelling specificity  
 To label hepatocytes – defined here as postnatal cells expressing HNF4α but 
not expressing BEC markers – we utilized a recombinant adeno-associated virus 
serotype 2/8 expressing Cre recombinase driven by the hepatocyte-specific  
promoter (thyroid hormone-binding globulin, AAV8-TBG-Cre) (Figure 2.8 A). 
This transduction was highly specific and effective, as all YFP
+
 labelled cells 
expressed HNF4α, a hepatocyte marker (>99%, 3948 YFP
+
 cells examined, N = 4 
mice), while none expressed KRT19, a BEC marker (2056 KRT19
+
 cells examined, 
N=6 mice) (Figure 2.8 A; (Gao et al., 2006; Malato et al., 2011; Wang et al., 2010; 
Yanger et al., 2013; Zincarelli et al., 2008)). This labelling pattern was true for liver 
analysed 9 months later (Figure 2.8 B). As an additional controlled, R26
YFP
 mice 
were administered with AAV8-Cre virus under the control of the ubiquitous 
cytomegalovirus (CMV) promoter (AAV8-CMV-Cre). Efficient marking of 
hepatocytes (HNF4α
+
 cells) with no marking of BECs (KRT19
+
 cells) was observed 
under both conditions demonstrating that viral tropism (and not the TBG promoter) 
accounts for hepatocyte-specific labelling (Figure 2.8 C-D). Additionally, all YFP
+
 
labelled cells were found to be positive for HNF4α with no labelling of non-
hepatocytes (Figure 2.8 E). 
  I further confirmed AAV-specificity by fluorescence-activated cell sorting 
(FACS). A BEC marker, EpCAM, was used to isolate BEC cells as has been  
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Figure 2.8 The AAV2/8 serotype specifically transduces hepatocytes 
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Figure 2.8 (A) Hepatocyte labelling was achieved by administrating AAV2/8 viruses 
containing Cre recombinase to R26
YFP 
mice under the control of the hepatocyte-specific 
thyroid binding globulin (TBG) promoter (AAV8-TBG-Cre) to determine the specificity, 
sensitivity, and tropism of viral infection. Immunofluorescent images show specific and 
efficient labelling of hepatocytes. Labelling of BECs was never observed following AAV 
(right panel, n= 6). (B) AAV8-TBG-Cre also results in persistent specific labelling of 
hepatocytes 9 months after infection; again there is no labelling of CK19
+
 BECs with this 
virus. (C, D) AAV2/8 viruses containing Cre recombinase under the control of the 
ubiquitous cytomegalovirus (CMV) promoter was used to further assess viral tropism. 
The images depict YFP
+
 lineage-labelled cells either 2 weeks (C) or 10-months (D) after 
injection of AAV8-CMV-Cre virus into R26
YFP
 animals. (E) Additionally, all YFP
+
 cells 
resulting from AAV8-TBG-Cre recombination (3948 cells counted) were HNF4α
+
. Scale 
bar=25µm.  
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Figure 2.9 Testing AAV2/8 serotype by fluorescence-activated cell sorting (FACS) 
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Figure 2.9 (A) BEC marker, EpCAM, overlaps and is co-expressed in CK19
+
 cells. 
(B) Uninjected (control) and injected (YFP
+
) R26
YFP
 animal livers were perfused 
and stained for EpCAM. Double positive cells for YFP and EpCAM were not 
detected in normal animals by FACS. 
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previously demonstrated (Okabe et al., 2009) (Figure 2.9). EpCAM overlaps and 
marks KRT19
+
 BECs (Figure 2.9 A). AAV-TBG-Cre injected R26
YFP
 mice were 
subjected to liver perfusion and further assessed by FACS to find no overlap 
between YFP
+
 cells and EpCAM
+
 cells, thus confirming BECs are not transduced. 
Hepatocyte pulse-chase outcome 
 I then subjected lineage-labelled AAV8-TBG-Cre; R26
YFP
 mice (“Pulse”) to 
the injury-recovery protocols used previously (“Chase”). Under these conditions,  
the percentage of labelled hepatocytes remained unchanged (Figure 2.10 B, C). 
Specifically, the labelling index for the pulse group (99.36±0.96%, 11,359 counted) 
did not decrease following recovery after DDC (99.31±1.00%, 5830 counted), CDE 
(99.83±0.17%, 1838 counted), CCl4 (99.75±0.38%, 1677 counted) or ANIT (100%, 
1944 counted). As a control, we performed 2/3 partial hepatectomy which also 
showed no change in the YFP labelling index (99.71±0.36%, 695 counted). Thus, 
by this sensitive labelling technique, I failed to find evidence that hepatocytes arise 
from non-hepatocytes after recovery from multiple models of ADC-inducing 
injuries. 
 
  
51 
 
 
 
 
 
Figure 2.10 Hepatocyte pulse-chase outcomes 
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Figure 2.10 (A) Liver histology (haematoxylin and eosin, left panel) and 
immunofluorescence (right panel) of uninjured “pulse” liver. (B) Liver histology 
returns to normal following injuries with DDC, CDE, CCl4, ANIT and PH with no 
appreciable change in the frequency of hepatocyte labelling. Scale bar=50µm.  (C) 
Quantification of hepatocyte labelling following AAV injection (“Pulse”) and  
recovery from DDC, CDE, CCl4, ANIT and PH injuries. Labelling index was 
quantified from 6, 6, 4, 4, 2 and 2 animals for each of the conditions, respectively 
(mean ± SD). Absolute numbers of cells counted for pulse and chase are provided 
in the text.  
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2.3 Summary 
 In this study, I have used two distinct lineage tracing approaches to test the 
hypothesis that regeneration from toxin-induced liver damage is mediated by FSCs. 
First, I genetically labelled KRT19-expressing BECs and ADCs – the tissue 
compartment in which liver stem cells are believed to reside – and found no 
evidence that these cells give rise to hepatocytes in the four injury models tested. 
Second, we labelled hepatocytes with high efficiency and specificity, and found that 
there was no decrease in the labelling index with the same types of injury, a result 
that is consistent with the notion that new hepatocytes are derived from pre-existing 
hepatocytes.  
 In addition, in collaboration with Dr. David Knigin in Dr. Eli Pikarsky’s 
laboratory at the Hebrew University, Israel, we utilized an unbiased approach using 
nucleoside analogue labelling to trace the fate of highly proliferative liver cells. 
Stem cells contribute to tissue homeostasis and regeneration by generating rapidly-
dividing progeny – referred to as transient amplifying (TA) cells – which expand 
prior to final differentiation (Blanpain et al., 2007). ADCs with their high 
proliferative index are characterized as liver TA cells (Alison et al., 2004; Hu et al., 
2007; Jensen et al., 2004). Teta et al. have previously reported that TA cells (Teta et 
al., 2007) can be labelled by incorporation of two thymidine analogues (i.e. dual-
labelling) when administered in succession. Adopting these methods for the liver, 
we found no evidence that rapidly-dividing non-hepatocytes differentiated into 
hepatocytes in the course of CDE-mediated injury. Taken together, these data 
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suggest that ADCs and other non-hepatocyte populations do not contribute 
significantly to hepatocyte neogenesis during liver regeneration, complementing the 
results from our genetic approaches. 
  Our results do not eliminate the possibility that under more demanding 
circumstances ADCs could exhibit bipotency. Likewise, we cannot rule out the 
possibility that our lineage labelling techniques have labelled a small subset of 
hepatocyte-like cells that remain multipotent. However, the finding that all cells labelled 
with AAV8-TBG-Cre (out of nearly four thousand examined) exhibit a mature 
hepatocyte phenotype argues against this possibility.  Moreover, IdU/CldU labelling 
experiments failed to reveal such a rapidly dividing (and expanding) subset of 
hepatocytes. Thus, our data are most consistent with a scenario in which ADCs play a 
very minor, if any, role undetectable using our tools with new adult hepatocytes coming 
from pre-existing hepatocytes, not only following partial hepatectomy but in the setting 
of toxin injuries as well.  
Finally, these conclusions have not fully addressed the data from electron 
microscopy studies which reveal  that following injury with hepatotoxins, cells with 
ultrastructural features of both ductular cells and hepatocytes, a “transitional” cell 
phenotype, emerge within the liver lobule (Factor et al., 1994). Due to their median size 
compared to other ADCs and hepatocytes, and variable nucleocytoplasmic rations, 
mitochondrial content, and glycogen rosettes, these observations allude to ADCs being a 
heterogeneous population of cells. The cell of origin for these intermediate-looking cells 
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exhibiting features “between” hepatocytes and BECs will be addressed in the next 
chapter.  
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3.1 Introduction 
 In adult tissues, rates of cell birth and death are tightly controlled to 
maintain tissue mass. During amphibian regeneration, de-differentiation and/or 
transdifferentiation is a major source of new cells (Nacu and Tanaka, 2011). By 
contrast, mammalian regeneration is driven by the replication of existing cells or 
differentiation from stem cells. Transdifferentiation, or cellular reprogramming, has 
been observed in mammals following the introduction of defined factors in vivo 
(Xie et al., 2004; Zhou et al., 2008), but spontaneous inter-conversion of 
differentiated cells seems to occur only in the setting of strong selective pressure 
(Thorel et al., 2010). “Metaplasia” – a condition in which the replacement of one 
tissue type with another predisposes to cancer – may involve cellular 
reprogramming, but the connection between metaplasia at the tissue level and 
transdifferentiation at the cellular level remains unresolved (Slack, 2009).  
 The mammalian liver is exceptional among regenerative organs in that the 
mode of injury is thought to dictate the cellular mechanism of recovery. Following 
partial removal of the liver (partial hepatectomy; PHx), liver mass is restored by 
replication and/or growth of existing cells (Miyaoka et al., 2012), whereas 
following toxin-mediated injury, animals and humans exhibit an accumulation of 
atypical ductal cells (ADCs) within the liver, often referred to as “oval cells” 
(Farber, 1956; Popper et al., 1957). In this study, we sought to determine whether 
cellular plasticity underlies the regenerative response of the liver. 
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3.2 Results 
3.2.1 Notch mediated reprogramming 
 In new-born mice, immature hepatocytes remain responsive to Notch signals 
and undergo a fate switch, becoming biliary epithelial cells (BECs) upon ectopic 
activation of the pathway (Zong et al., 2009). To determine whether this plasticity 
and competence was true in the adult animal, we induced Notch signalling in adult 
hepatocytes. We bred R26
YFP
 mice to R26
NICD
 mice, which harbour a Cre-inducible 
constitutively active form of Notch1 (Murtaugh et al., 2003; Zong et al., 2009). 
Next, we simultaneously labelled cells and induced Notch signalling using the same 
AAV8-TBG-Cre virus. As predicted, infection of bigenic R26
NICD/YFP
 mice with 
AAV8-TBG-Cre resulted in the activation of Notch signalling (assessed by Hes1 
expression) in more than 95% of hepatocytes. Over the course of Notch signalling, 
lineage-labelled cells started to express KRT19 and by 6 weeks, 23% of all KRT19 
cells were YFP
+
.  Hence, adult hepatocytes retain this plasticity and ectopic 
activation of Notch signalling is sufficient to reprogram a subset of hepatocytes into 
BEC-like cells (Yanger et al., 2013). 
3.2.2 Injury mediated reprogramming 
Injury induced “intermediate cells” 
 Toxic liver injuries result in an atypical ductal cell (ADC) or “oval cell” 
response. ADCs have a biliary phenotype, but their arrangement into an intricate 
anastomosing configuration that extends into the hepatic lobule gives them a 
histological appearance that is distinct from normal bile ducts (Desmet, 1985). We 
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noted that the reprogrammed BEC-like cells resulting from Notch activation 
resembled ADCs, prompting us to hypothesize that some ADCs might be 
hepatocyte-derived. To test this possibility, I administered AAV8-TBG-Cre to 
R26
YFP
 mice and, following a washout period, treated animals with the hepatotoxin 
DDC (3,5-diethoxycarbonyl-1,4-dihydrocollidine). As previously shown, DDC 
treatment was associated with a robust ADC response during which a substantial 
fraction of hepatocytes and BECs underwent turnover. Within 1-2 weeks of DDC 
exposure, cells that co-stained with biliary and hepatocyte markers were readily 
detectable. These bi-phenotypic “intermediate” cells were most abundant in peri-
portal regions and many were binucleated (for example, 41% of A6
+
HNF4α
+
 cells 
had two nuclei; Figure 3.1 A). Staining for the YFP lineage marker demonstrated 
that these intermediate cells were of hepatocyte origin, appearing within 2 weeks 
(Figure 3.1 B)  
Conversion of hepatocytes into mature BECs 
 After 2-3 weeks of DDC treatment, YFP-labelled hepatocytes started 
expressing the mature BEC marker, KRT19. YFP
+
 KRT19
lo
 cells (weak KRT19 
expression) appeared first at this time point (Figure 3.2A).  After 6 weeks of DDC 
treatment, a time-point when ADCs were most plentiful, I observed that many YFP
+
 
cells had assumed a biliary morphology and co-stained with OPN, A6, Sox9, or 
KRT19 (Figure 3.3 A). At this time-point, YFP
+ 
cells with strong KRT19 staining 
(KRT19
hi
) comprised 4.4% of the total KRT19
+ 
population (Figure 3.2 B). The  
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Figure 3.1 Appearance of “intermediate” cells expressing both biliary and 
hepatocyte makers upon injury 
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Figure 3.1 (A) Mice treated with DDC for 1 week exhibit co-staining with a hepatocyte 
marker (HNF4α and one of three biliary markers (OPN, Sox9, A6). Double positive cells 
have a hepatocyte morphology (arrowheads) and many are binucleated (arrows). The 
images are representative of multiple experiments. (B) “Intermediate” cells emerge early 
following treatment with DDC (2 weeks). Most YFP
+
 cells with co-staining for the 
biliary markers Sox9, OPN, or A6 (arrowheads) retain a hepatocyte morphology at this 
time-point.  Scale bars=25µm. 
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Figure 3.2 Low expression of KRT19 in hepatocytes during injury 
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Figure 3.2 (A) Hepatocyte-derived CK19
+
 cells following injury (6 weeks of DDC) can 
be divided into CK19
lo 
cells and CK19
hi 
cells based on the intensity of staining 
(arrowheads denote CK19
lo
 and arrow denotes CK19
hi
). (B) All CK19
lo 
cells are YFP
+
 
(100%), while a fraction of CK19
hi 
cells are also YFP
+
 (4.4%) (N=4 animals). CK19
lo 
cells are never observed in control livers and appear early in the injury process (after 2-3 
weeks of DDC), whereas YFP
+
CK19
hi
 cells (such as those in Figure 3.3), emerge later. 
Scale bar=25µm. 
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Figure 3.3 Direct evidence for hepatocyte-to-ADC reprogramming in vivo 
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Figure 3.3 (A) Co-staining of the biliary markers (i) OPN, (ii) Sox9, (iii) A6 and (iv) 
CK19 with the YFP lineage label is observed following DDC treatment (6 weeks), BDL 
(2 weeks), or PHx (2 weeks); co-stained cells are denoted with arrowheads. Note that 
many of the co-stained cells are smaller than neighbouring hepatocytes. (B) Biliary 
markers are induced in a stepwise fashion following injury. The percentage of marker
+
 
cells (i.e. cells that stained positive for OPN, Sox9, A6, or CK19) which co-express the 
YFP lineage label is shown. Both CK19
hi
 and CK19
lo
 cells were included in the analysis. 
Double positive cells were not detected in vehicle-treated livers. Each bar represents the 
mean (+/- SE) of at least 3 mice; a minimum of 950 marker
+
 cells were examined for 
each data point. Scale bars=25µm. 
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frequency of co-staining with YFP depended on the biliary marker used, ranging 
from 48.1% of OPN
+
 cells to 14.3% of KRT19
+
 cells (Figure 3.3 B). 
To determine whether this phenotypic conversion is a generalized feature of 
liver damage, I performed other types of injury in animals with lineage-labelled 
hepatocytes. As with DDC treatment, I observed changes in the morphology of 
YFP
+
 cells and co-staining of YFP and biliary markers in the setting of ductular 
reactions caused by other stimuli – including bile duct ligation (BDL) and other 
injuries (Figure 3.3 A-B, Figure 3.4, respectively) – although the frequency of co-
staining varied with the type of injury). Following PHx, by contrast, YFP
+
 cells that 
had adopted a biliary morphology or stained weakly for KRT19 were never 
observed  (N=5), although staining for OPN, Sox9, and (rarely) A6 was seen in 
some hepatocytes (Figure 3.3 A,B). These results suggest that toxin-based injuries 
and BDL – insults that provoke an ADC response – are associated with stepwise 
hepatocyte-to-BEC reprogramming while PHx – an injury that predominantly 
involves cell replication and hypertrophy – does not lead to cellular conversion. 
Cellular characterization of reprogrammed BECs 
The appearance of bi-phenotypic cells in a variety of rodent injury models 
prompted us to analyse human liver specimens for evidence of hepatocyte-to-BEC 
reprogramming in the setting of injury.  As described for other liver diseases with 
biliary involvement (Limaye et al., 2008a), I found abundant cells which co-
expressed the hepatocyte markers HNF4α and HepPar1 and the BEC marker Sox9 
in liver sections from patients with several types of liver disease, whereas such cells  
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Figure 3.4 Hepatocytes express biliary cell markers in multiple liver toxin injuries 
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Figure 3.4 Co-staining of various BEC markers, OPN, Sox9 and CK19, appear in YFP
+
 
hepatocytes in various toxin injuries such as ANIT diet (A), CCl4 administration (B)  and 
CDE diet (C); co-stained cells denoted by arrowheads. (D) The percentage of marker
+ 
cells in YFP
+
 hepatocytes. Each bar represents the mean of (+/- SE) of at least 3 mice. 
Scale bar=25 µm. 
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were never observed in control human liver specimens (Figure 3.5). These results 
suggest that the cellular plasticity observed in the rodent injury models may also 
operate during human liver injury. 
To determine the extent to which hepatocyte-derived BECs acquire features 
of normal BECs, I performed a more detailed morphological and molecular analysis 
of DDC-treated livers. Within 3 weeks of DDC treatment, YFP
+
 cells underwent 
dramatic morphological changes, including the acquisition of a distinctive apical-
basal polarity (detected by staining for PKCζ and Par6), a reduction in cell size, and 
coalescence into neo-lumens (Figure 3.6 A). YFP
+
 cells in DDC-treated livers also 
exhibited the development of primary cilia, a biliary-specific organelle marked by 
acetylated-tubulin (Ac-tub; Figure 3.6 B). 
Next, I sought independent evidence for a hepatocyte origin of ADCs using 
ploidy characterization. More than 30% of normal murine hepatocytes are 
binucleated, whereas BECs are mono-nucleated (Gupta, 2000). We reasoned, 
therefore, that some hepatocyte-derived ADCs might be binucleated. Consistent 
with this notion, binucleated ADCs were found in DDC-treated livers, whereas 
none were detected in control livers (Figure 3.6 C-D; 0.6% vs. 0.0%). All 
binucleated ADCs expressed the YFP lineage maker, suggesting that polyploidy 
was restricted to hepatocyte-derived BECs (Figure 3.6 C). 
Molecular characterization of reprogrammed BECs 
 Additionally, I obtained molecular evidence that the hepatocyte-derived 
BECs closely resemble normal BECs. Hepatocyte-derived YFP
+
 BECs were  
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Figure 3.5 Human liver diseases exhibit “intermediate” cell phenotype 
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Figure 3.5 Sox9 segregates BECs from hepatocytes marked with HNF4α or HepPar1 in 
normal human liver (A). Co-expression of Sox9 in hepatocytes is found in liver diseases 
such as (B Joubert’s Syndrome, (C) chronic Hepatitis C and (D) INH-induced massive 
hepatic necrosis. Scale bar=25 µm. 
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Figure 3.6 Hepatocytes undergo morphological changes during reprogramming 
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Figure 3.6 (A) YFP
+
 hepatocytes change their morphology after DDC injury, 
organizing into duct-like structures with neo-lumens marked by the apical polarity 
markers PKCζ and Par6 (arrowheads). (B) Reprogrammed cells have cilia, marked 
by acetylated tubulin (6 weeks, Ac-tub; pink asterisk). (C) Reprogramming leads to 
binucleated ADCs. Sections of liver from AAV8-TBG-Cre-labelled animals given 
DDC were co-stained with DAPI (grey/blue), YFP (green) and CK19 (red) and 
examined by confocal microscopy. Binucleated ADCs were present in the YFP
+
 
population. (D) Quantification of binucleated BECs in labelled mice given normal 
chow (AAV vehicle) or DDC (AAV DDC); the number of cells counted (N=3 mice 
in each group) is shown. Scale bars=10µm. 
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captured using FACS and assessed by qPCR for multiple BEC markers. These 
reprogrammed cells exhibited transcript levels for these genes comparable to those 
of bona fide BECs (Figure 3.7 A-C) indicating that they had acquired many of the 
transcriptional hallmarks of normal biliary cells. Notably, hepatocyte-derived BECs 
and YFP
+
 hepatocytes (including those at early stages of biliary reprogramming) 
did not express the hepatoblast marker α-fetoprotein (AFP), suggesting that the 
conversion process does not go through a dedifferentiation step (Figure 3.7 D). 
Collectively, these results indicate that following injury in vivo, hepatocytes can 
turn into cells that closely resemble normal BECs at the morphological, structural, 
and molecular level. 
3.2.1 Notch signalling is required for reprogramming 
 Finally, we examined the molecular mechanism underlying the 
hepatocyte-to-BEC conversion. As Notch overexpression itself induced hepatocyte 
reprogramming, we employed mice with a liver-specific deletion of RBP-Jκ – an 
essential component of the canonical Notch pathway – to determine whether Notch 
signalling is also required for reprogramming under injury conditions. We and 
others have shown that deletion of RBP-Jκ in the embryonic liver using the AFP
Cre
 
strain results in bile duct paucity due to Notch’s role in biliary specification (Sparks 
et al., 2010; Zong et al., 2009). We found that treatment of AFP
Cre
; RBP
L/L
 mice 
(referred to as “AFP-RBP” mice) with DDC resulted in a marked reduction in the 
ADC response compared to controls, a result that provides genetic evidence that 
Notch signalling is required for the generation of ADCs (Yanger et al., 2013).  
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Figure 3.7 Molecular analyses of hepatocyte-derived/reprogrammed BECs 
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Figure 3.7 (A) AAV8-TBG-Cre injected R26
YFP
 mice underwent DDC injury and livers 
were sorted and collected for 3 different populations: YFP
+
 hepatocytes (P8), EpCAM
+
 
YFP
+
 double positive reprogrammed BECs (P7) and EpCAM
+
 BECs (P6). (B) Schematic 
of cellular population isolated for downstream analysis such as qPCR. (C) qPCR analysis 
of BEC markers gene expression levels comparing populations isolated from (B). 
Expression levels relative to housekeeping gene, GAPDH. (D) Expression level for the 
hepatoblast marker, AFP, was negligible in all populations including reprogrammed 
BECs. Positive control for AFP expression was whole livers from E11.0 embryos.   
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However, since AFP
Cre
 mediates deletion in embryonic hepatoblasts, AFP-RBP 
mice lack RBP-Jκ in both hepatocytes and BECs. Hence, the defective ADC 
response could be the result of RBP-Jα loss in either, or both, of these cellular 
compartments.  
 To determine whether Notch is involved in hepatocyte-to-ADC 
reprogramming, I assessed the degree of reprogramming in the context of Notch 
signalling impairment via RBP-Jκ knockdown. In order to do so, I administered 
AAV8-TBG-Cre to RBP
L/∆
 mice harbouring one “floxed” allele and one null allele 
of RBP-Jα (“L/Δ”) and for controls administered either 1) AAV8-TBG-GFP virus 
lacking Cre to control RBP
L/L
 mice (“L/L’) or 2)  AAV8-TBG-Cre  to RBP
L/WT
 
mice harbouring one wild-type allele of RBP-Jα (“L/WT”; Figure 3.8 A). Following 
a week-long washout period, animals in both groups were fed DDC for 3 weeks. As 
expected, control animals (L/L, L/WT) exhibited abundant bi-phenotypic cells, 
(Figure 3.8 B, D; left panels).  By contrast, RBP-Jκ KO mice (L/Δ) exhibited 
dramatic decreases in bi-phenotypic cells (Figure 3.8 B, C; right panels) and 
hepatocyte-derived Sox9
+
 and OPN
+
 cells (Figure 3.8 D, E; right panels). This 
result indicates that RBP-Jκ is required for biliary reprogramming. 
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Figure 3.8 Hepatocyte reprogramming requires Notch signalling 
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Figure 3.8 (A) Schematic of simultaneous deletion of RBPJκ and lineage tracing of 
hepatocytes. (B-E) Mice with hepatocyte-specific deletion of RBP-Jκ have a 
significant reduction in the number of “intermediate” cells. (B) RBP-Jκ deletion 
results in a reduction in the percentage of HNF4α “intermediate” cells co-localizing 
with Sox9
+
 or OPN
+
 cells after DDC treatment (3 weeks). (C) Quantitation of (B), 
depicting the percentage of Sox9
+
 or OPN
+
 cells which co-stain with HNF4α. (D) 
Concomitant hepatocyte labelling and RBP-Jκ deletion results in a reduction in the 
percentage of hepatocyte-derived Sox9
+
 or OPN
+
 cells after DDC treatment (3 
weeks). (E) Quantification of (D), depicting the percentage of Sox9
+
 or OPN
+
 cells 
which carry the YFP lineage marker (N=4 mice each group). Scale bars=25µm. 
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3.3  Summary 
 In summary, I have shown that hepatocytes initiate an in vivo differentiation 
program following injury that results in functioning as FSCs in their conversion into 
biliary cells. This process occurs in a stepwise fashion that involves the induction of 
biliary markers, a decrease in cell size, formation of a polarized epithelial layer, and 
the formation of new and potentially functional organelles. Thus, we also address 
the long-standing observations from electron microscopy studies revealing cells 
with both hepatocyte and biliary features in toxin-injured livers (Factor et al., 1994), 
with hepatocytes being the cell of origin for a subset of the ADC population 
discussed in Chapter 2. These results thus provide a dramatic example of how 
cellular reprogramming – a process that has been mainly associated with lower 
organisms – can contribute to mammalian regeneration. This plasticity is mimicked 
by overexpressing a single transcription factor, Notch, a signalling pathway utilized 
during biliary specification in liver development. Truncation of the pathway 
attenuates this reprogramming process and thus Notch signalling is required. Our 
findings also suggest that hepatocyte pliability may serve as a cellular source for the 
production of BECs in diseases that are characterized by loss or dysfunction of 
these cells, such as cholestasis or Alagille Syndrome. 
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4 DISCUSSION 
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The longstanding notion that ADCs are FSCs has been based largely on 
static observations, in vitro studies and cellular transplantation assays (Dorrell et al., 
2011; Huch et al., 2013; Wang et al., 2003a).  For example, Wang et al. (2003a) 
employed cellular fractionation to isolate distinct populations of non-parenchymal 
cells from DDC-treated chimeric mice, and then transplanted genetically marked 
cells from the ADC-containing fraction into conditioned recipients to test their 
potential when a selective pressure was applied. Since the transplanted cells were 
able to repopulate hepatocytes killed during the pre-transplant conditioning 
protocol, the authors concluded that ADCs give rise to hepatocytes. However, as the 
starting population was heterogeneous, this study could not rule out the possibility 
that the hepatocytes – with their nearly unlimited capacity for self-renewal – 
mediated the recovery. Moreover, the transplantation assay is a test of cell potential 
under selective pressure rather than cell fate in the absence of experimental 
perturbation. Hence, while repopulation studies suggest that fractions of cells that 
contain ADCs can give rise to hepatocytes under strong selective pressure, the fate 
of ADCs during normal liver regeneration is not addressed by this technique.  
 Similarly, in vitro studies which demonstrated that cells with a biliary/ADC 
phenotype can differentiate into hepatocyte-like cells have limitations (Dorrell et 
al., 2011; Okabe et al., 2009; Shin et al., 2011). In particular, such assays rely on 
the assumption that hepatocytes and BECs represent stable end-products of 
differentiation that are not easily inter-convertible, an assumption that might not be 
valid for cell types that retain a high degree of plasticity. In other words, if the 
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barrier to transdifferentiation between two cell types is low, such in vitro assays 
cannot serve as evidence for stem cell activity. Previous studies have demonstrated 
significant plasticity between hepatocytes and BECs in vitro (Grisham, 1980; 
Limaye et al., 2008b; Nishikawa et al., 2005; Tsao et al., 1984; Yaswen et al., 1984) 
and my own work and work from others has demonstrated significant plasticity in 
vivo (Michalopoulos et al., 2005; Yanger et al., 2013). Thus while cell 
transplantation and in vitro culture systems can provide insight into cell potential 
under these experimental conditions, lineage tracing permits a more accurate 
indication of cell fate. 
 Several groups have used lineage tracing to characterize the origin and fate 
of ADCs. Initial work employing [
3
H]-thymidine incorporation gave rise to 
discordant conclusions, with experimental evidence both favouring (Evarts et al., 
1987; Evarts et al., 1989) and refuting (Grisham and Porta, 1964; Rubin, 1964; 
Tatematsu et al., 1984) an ADC-to-hepatocyte differentiation lineage relationship. 
In addition, more recent lineage tracing studies have also led to disparate results 
(Friedman and Kaestner, 2011). As discussed earlier, results from the  Foxl1-Cre 
mice (Sackett et al., 2009) cannot stringently assess the bipotency of oval cells. As 
the promoter is not an inducible one, hepatocytes and biliary cells can both 
potentially activate Foxl independently and thus giving a false ontological 
conclusion of a progenitor-to-hepatocyte relationship.  More recently, several Cre-
based labelling- inducible drivers resulted in the inheritance of label in hepatocytes, 
although the contribution to the hepatocyte pool was low. For instance, Cre-based 
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labelling- employing osteopontin (Opn) gave rise to between 0.78%-2.45% of 
labelled cells co-staining with hepatocyte markers (Espanol-Suner et al., 2012). 
Similarly, in a study utilizing the Lgr5-inducible driver reports, the initial 
percentage of labelled hepatocytes was not reported but the authors claimed these 
cells arose from a non-hepatocyte Lgr5
+
 population that emerged and got labelled 
upon TM administration in the context of injury. These cells were further grown as 
organoid cultures and used for transplantation which  resulted in a total of 5 out of 
15 FAH-/- mice being successfully engrafted, of which  approximately 0.1-1% of 
hepatocytes were labelled (Huch et al., 2013). The authors of the study noted this 
result was in contrast to a more robust engraftment and 100% rescue displayed by 
hepatocyte transplantation in their previous studies (Azuma et al., 2007; Huch et al., 
2013).  
More dramatic evidence for liver progenitors was provided by Furuyama et 
al. (2011), who reported that a significant percentage (up to 90%) of the liver was 
eventually marked following pulse-labelling with a Sox9-CreER strain, a result 
which on face value is strong evidence for physiologically-active stem cells. By 
contrast, other studies utilizing a similar but separately constructed Sox9-CreER 
strain did not find evidence for such liver progenitors (Carpentier et al., 2011). 
Additionally, using a similar hepatocyte labelling method with adeno-associated 
virus – no decrease in labelling was observed following most forms of injury and a 
scant 1.3% reduction in labelling following CCl4 injury (an effect whose statistical 
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significance from baseline was not reported), indicating that stem cells play a 
minor, if any, role in liver homeostasis and regeneration (Malato et al., 2011). 
 The ability to reach strong conclusions about lineage is deeply dependent 
upon the specificity of the tracing tools employed. For example, the Opn-, Lgr5-, 
and Sox9 studies all rely upon the assumption that Cre-mediated recombination 
never occurs in hepatocytes; if such a lack of specificity were to exist, even to a 
small extent, one would be left with the impression that hepatocytes are derived 
from BECs or ADCs, when in fact no such progenitor-progeny relationship existed. 
An example of this is the RIP-CreER strain that has been used for numerous β-cell 
studies in the pancreas, which was shown to induce recombination independent of 
TM administration (Liu et al., 2010). Several other studies have highlighted the 
importance of using appropriate controls and careful handling with TM used for the 
inducible strains and studies (Anastassiadis et al., 2010; Danielian et al., 1998; 
Reinert et al., 2012). Thus, numerous controls have to be done to ensure “tightness” 
of inducible strains to show there is no “leakiness” in the absence of TM in normal 
and perturbed animals. We speculate that this technical point accounts for the 
discrepancy between our results and those of others who have reported liver 
progenitor cell activity in vivo. Indeed, when I tested the specificity of the same 
Sox9-CreER strain (Soeda et al., 2010) used by Furuyama and colleagues with a 
R26
YFP
 reporter, I found that this strain confers substantial hepatocyte labelling 
(Figure 4.1). This result is consistent with the observation that Sox9 is induced in 
hepatocytes by TM administration alone (Carpentier et al., 2011) and under 
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pathological conditions (Yanger et al., 2013). Hence, “ectopic” Sox9 expression in 
hepatocytes, resulting in their labelling, may have led to the conclusion that they 
were derived from biliary cells. A similar phenomenon may have contributed to the 
low-level of hepatocytes marked with Opn-CreER (Espanol-Suner et al., 2012) and 
Lgr5-CreER (Huch et al., 2013), as hepatocytes have a propensity for expressing  
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Figure 4.1 Sox9-CreER labels BECs and hepatocytes 
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Figure 4.1 (A) Schematic of Sox9-CreERanimal crossed to R26
YFP
 reporter mice to 
label cells upon TM administration. (B) 6-8 week adults given 40 mg of TM in a 1 
week pulse result in labelling of hepatocytes (arrowheads) and inefficient labelling 
of KRT19
+
 BECs (arrows). (C) A 1 day pulse in post-natal animals administered 
TM via the mother results in unspecific labelling of hepatocytes (arrowheads) while 
inefficiently labelling BECs (arrows). Scale bar=50μm.   
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certain biliary markers including OPN, upon stress (Limaye et al., 2008a; Yanger et 
al., 2013).  As a “terminal” biliary marker, KRT19 appears to be an exception to 
this specificity problem; unlike Sox9 and Opn, hepatocytes do not express KRT19 
upon injury and become KRT19
+
 only after prolonged toxin exposure as part of a 
hepatocyte-to-BEC reprogramming process (Figures 3.1-3). Hence, Krt19-CreER 
mice are likely to represent a more specific – and hence more reliable – tool for 
assessing the contribution of BECs and ADCs to liver repopulation. 
Our results are in accordance with older studies that utilized [
3
H]-thymidine 
incorporation, immunostaining, and electron microscopy to examine the origins of 
ADCs in vivo (Factor et al., 1994). In those experiments, newly emergent ADCs 
had ultrastructural features of hepatocytes and were commonly found in close 
apposition to hepatocytes as they expanded into the lobule. In light of our lineage 
tracing results that show hepatocytes functioning as FSCs, I propose that these 
observations reflect the retention, rather than the acquisition, of hepatocyte features 
during reprogramming, an idea that first emerged more than fifty years ago when 
ADCs were initially described as “ductular hepatocytes” (Leduc, 1959). 
The notion that a differentiated cell can be—under certain circumstances—
recruited to function as a stem cell is related to the larger concept of cellular plasticity. In 
many organisms, terminally differentiated cells are able to undergo a process of 
dedifferentiation to reconstitute the stem cell state. In the  Drosophila male germline, for 
example, cells that have undergone the first step in spermatogonial differentiation (to 
become “transient amplifying” cells) can reverse direction and take on a stem cell 
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identity (Brawley and Matunis, 2004). In mammalian studies, the landmark discovery 
that fibroblasts can be converted to pluripotent cells, known as induced pluripotent stem 
cells (iPSCs) (Takahashi and Yamanaka, 2006) , utilizes the ectopic expression or 
activity of defined factors in vitro. In 2004, Wagers and Weissman established a set of 
stringent criteria by which to assess bona fide reprogramming events in vivo, a list that 
includes demonstrating proper integration of the trans-differentiated cells within the 
tissues. My studies regarding the conversion of hepatocytes to BECs fulfil this, and do so 
in a robust manner unique to the liver and not shown in other organs.  
Using a lineage tracing approach, I show that hepatocytes are FSCs and can 
indeed undergo a robust process of biliary reprogramming, a process dependent on Notch 
signalling. We have shown that following the expression of a single transcription factor 
(NICD) or multiple types of hepatic injury, hepatocytes gradually lose their identity and 
acquire a biliary phenotype in vivo. As part of this Notch-dependent process, our studies 
suggest that BEC reprogramming occurs as a cascade, transitioning through an 
intermediate state, characterized by the co-expression of hepatocyte- and BEC-specific 
transcription factors, and adopting morphologic features of BECs (Figure 4.2). Given the 
role that Notch plays as a major fate determinant during normal biliary differentiation 
(Si-Tayeb et al., 2010; Zong et al., 2009), we postulate that adult hepatocyte-to-BEC 
reprogramming is a recapitulation of this developmental process. However, the question 
regarding whether a ‘dedifferentiation’ process is involved is not very clear as I could not 
detect any levels of α-fetoprotein, AFP, a marker of hepatoblasts - progenitor cells during 
liver development, in the reprogrammed cells.  
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Figure 4.2 Model for hepatocyte-to-ADC reprogramming 
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Figure 4.2 Toxin-based injuries or Notch-signalling initiates a hepatocyte-to-ADC 
reprogramming cascade. This cascade includes transcriptional changes, alterations 
in cellular morphology and eventually function.  
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Several features of liver cell reprogramming are reminiscent of the process of 
iPSC reprogramming. The route from hepatocyte to BEC is a gradual one involving a  
 “reprogramming cascade,” with distinct and sequential changes in morphology and gene 
expression patterns. For example, hepatocytes acquire primitive biliary features (e.g. 
decrease in cell size and re-alignment of cell polarity) and express primitive biliary 
markers (e.g. OPN and Sox9) soon after injury. Similarly, iPSC generation being a 
multistep process involves early phases of reprogramming  with cells decreasing in size, 
obtaining epithelial cell characteristics  and upregulating various proliferative genes 
(Plath and Lowry, 2011). It is only later that reprogrammed hepatocytes adopt more 
mature cellular and molecular features of BECs, such as the ability to form tubes, cilia, 
and express the definitive biliary marker, KRT19. Likewise, the late phase of iPSC 
reprogramming is characterized by the generation of ESC-like colonies and by the loss of 
repressive chromatin marks leading to the expression of pluripotent genes such as 
endogenous Oct4 (Plath and Lowry, 2011).  
Despite expression of all transcription factors, iPSC reprogramming is 
heterogeneous (Carey et al., 2009),  as exhibited in our hepatocyte reprogramming study.  
During injury, hepatocytes located closest to the portal veins, known as “Zone 1,” 
undergo biliary reprogramming with a much higher efficiency than “Zone 3” 
hepatocytes, which are centrally located within the liver lobule and do not 
reprogram fully. Similarly, despite activation of the Notch pathway in more than 
95% of hepatocytes (including all zones), only Zone 1 and Zone 2 hepatocytes 
undergo biliary conversion, though not with 100% efficiency. This result suggests 
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that heterogeneity in reprogramming is a result of either a lack of competence of 
Zone 3 hepatocytes to be converted due, for example, to a difference in epigenetic 
state or a requirement for a second signal that is absent from Zone 3. For instance, 
Notch signalling is not the sole pathway involved in biliary specification during 
development (Si-Tayeb et al., 2010). Thus, full maturation of hepatocyte 
reprogramming may require, in addition to Notch activation, a “second-hit” from 
other signalling pathways such as TGF-β, akin to the requirement of Nanog for the 
final stages of iPSC reprogramming (Silva et al., 2009). Thus, these extracellular 
signals may be more permissive in the diverse extracellular milieu zone 1 
hepatocytes are in with the biliary cells and fibroblasts around the portal veins, 
which are void in the area zone 3 hepatocytes are in. While proliferation is required 
for iPSC generation, (Takahashi and Yamanaka, 2006), other forms of 
reprogramming such as acinar-to-β cell reprogramming  (Zhou et al., 2008) and 
heterokaryon-generated iPSCs do not (Bhutani et al., 2010). In our system, injuries 
that provoke biliary reprogramming are associated with a high degree of cellular 
turnover and occur over a long period of time (2-4 weeks); hence, more refined 
methods will be needed to probe this cellular conversion process. 
Many clinical implications arise from our findings. The prevalence of the 
phenomenon suggests that cellular reprogramming is a generalized component of 
the liver’s normal response to injury, particularly those injuries cause by multiple 
toxins. I and others have shown that indeed, various human diseases display 
characteristics of this reprogramming with the abundance of “intermediate”/bi-
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phenotypic cells (Figure 3.5) (Limaye et al., 2008a). Cancer studies have also 
revealed that “extreme” or prolonged reprogramming could be detrimental. For 
instance, Notch signalling in the liver (our findings in Appendix 1), in the 
hepatocytes (Fan et al., 2012; Sekiya and Suzuki, 2012) and prolonged toxin injury 
(Wang et al., 2012) can lead to hepatocellular carcinoma, cholangiocarcinomas or 
both, respectively. Thus, this transition and switch between hepatocyte 
reprogramming being a reparative process to potentially becoming disease initiating 
is an interesting question to probe further. 
Our findings also suggest hepatocyte pliability being a potential cellular 
source for the production of BECs in diseases such as cholestasis or Alagille 
Syndrome that are characterized by loss or dysfunction of these cells. Alagille 
Syndrome is a paediatric, genetic autosomal diseases affecting 1/70,000 new-borns 
(Piccoli and Spinner, 2001). It is characterized by jaundiced and cirrhotic livers due 
to the build-up of bile caused by the lack of BECs for efficient transportation out of 
the liver, though the severity is heterogeneous (Alagille et al., 1987; Piccoli and 
Spinner, 2001). Interestingly, human patients display mutations within the Notch 
pathway, with a significant portion having JAG1 mutations while a smaller portion 
have NOTCH2 mutations (Li et al., 1997; McDaniell et al., 2006; Oda et al., 1997). 
Results of mouse mutation models of Jag1 (Xue et al., 1999) and Notch2 (McCright 
et al., 2001) were initially dismissed as not mirroring the BEC paucity seen in 
human samples, except when both mutations were combined (McCright et al., 
2002). I have found, contrary to these earlier studies, both mutations promote 
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defects in biliary formation in early post-natal livers, with the double mutant animal 
being the most severe (P2, P16 (Figure 4.3)). Notably, at later time points, the 
double mutant animals displayed “intermediate-looking” cells, with hepatocyte-
looking cells starting to adopt a BEC-phenotype by expressing OPN but not KRT19 
(P16, (Figure 4.4)). This suggests that hepatocyte reprogramming may potentially 
be a compensatory mechanism Alagille livers use to make up for the BEC paucity 
to survive into adulthood. Understanding the mechanism underlying this process 
may therefore have therapeutic relevance. 
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Figure 4.3 Biliary development in Alagille mice 
98 
 
Figure 4.3 Single (Jagged1, Notch2) and compound mutants (J1/N2) exhibit BEC 
paucity compared to wildtype litter mates in early post-natal livers. Scale bar=25 
µm. 
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Figure 4.4 Intermediate cells in double mutant Alagille livers 
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Figure 4.4 BEC markers OPN and KRT19 overlap and mark BEC in wildtype and 
Jagged1 and Notch2 mutant animals. Double mutant (J1/N2) liver samples have 
more OPN single positive cells than OPN/KRT19 double positive cells 
(arrowheads). Scale bar=25 µm. 
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5 APPENDIX 1 : ROLE OF NOTCH SIGNALLING IN 
HEPATOCELLULAR CARCINOMA
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 This appendix, with modifications, has been published: Villanueva, A., Alsinet, C., Yanger, K., Hoshida, 
Y., Zong, Y., Toffanin, S., Rodriguez-Carunchio, L., Solé, M., Thung, S., Stanger, B.Z., Llovet, J.M. Notch 
signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. 
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5.1 Introduction 
This work was done in collaboration with Dr. Augusto Villanueva and Dr. Clara 
Alsinet (laboratory of Dr. Josep Llovet; University of Barcelona, Spain), resulting in a 
joint first-authorship among the three of us. We utilized bioinformatics from both human 
patients and mice along with in vivo mouse models and cell culture experiments to study 
the role of Notch signalling in hepatocellular carcinoma (HCC).   
Hepatocellular carcinoma (HCC) 
Primary liver cancer is the third leading cause of cancer death worldwide (Jemal 
et al., 2011), and its incidence in the United States has tripled between 1975 and 2005 
(Altekruse et al., 2009).The most frequent subtype is HCC, which has a complex 
pathogenesis related to its diverse etiologic factors including cirrhosis because of viral 
hepatitis (B and C) and/or alcohol abuse. Overall, less than 30% of newly diagnosed 
HCC patients are eligible for curative therapies such as resection, liver transplantation, or 
local ablation (Llovet et al., 2003). Patients diagnosed at advanced stages have a bleak 
prognosis, although the recent identification of sorafenib as an effective molecular 
therapy has extended their survival to a median of approximately 1 year (Llovet et al., 
2008). Although this therapy is not curative, it has changed the landscape of translational 
research in the field, underscoring the importance of dissecting the molecular drivers of 
HCC. 
The Notch pathway is an evolutionarily conserved signalling module that 
participates in embryonic cell fate decisions and regulates stem/progenitor cell states 
(Zaret, 2008).In the liver, Notch acts in a temporal- and dose-dependent manner to  
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coordinate biliary fate and morphogenesis (Zong et al., 2009). A causative role for Notch 
signalling is well established in T-cell acute lymphoblastic leukaemia, where mutations 
or chromosomal aberrations affecting the NOTCH1 gene are found with high frequency 
(Ranganathan et al., 2011). In addition, activation of the Notch pathway has been 
described in several other solid tumours (Santagata et al., 2004; Westhoff et al., 2009). 
Data regarding Notch involvement in HCC are limited and ambiguous in terms of 
antitumoural effects following its inhibition (Giovannini et al., 2009; Qi et al., 2003; 
Wang et al., 2009). Of note, none of the previously reported studies on Notch and HCC 
included genetic engineered models for pathway deregulation. We previously developed 
a series of gain-of-function and loss-of-function reagents to characterize the role of Notch 
during liver development (Zong et al., 2009). Herein, we report that long-term exposure 
to constitutive Notch signalling in the liver induces HCC in mice with high penetrance 
and that Notch pathway activation occurs in roughly one-third of human HCCs. 
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5.2 Results 
5.2.1 Liver-Specific Activation of Notch Pathway Promotes Oncogenesis 
We sought to evaluate long-term effects of Notch signalling in vivo by using 
bigenic AFP-NICD mice, in which Cre-mediated recombination in embryonic 
hepatoblasts results in the expression of a constitutively active form of Notch1 in > 95% 
of hepatoblasts and cholangiocytes postnatally (Zong et al., 2009) (Figure 5.1 A). At 6 
months of age, AFP-NICD mice developed liver tumours at an estimated frequency of 
33% (1/3) and 50% (2/4) at 9 months. Beyond 12 months, all AFP-NICD mice showed 
macroscopic liver tumours (12/12, 5.1 B), whereas none of the control monogenic mice 
(R26
NICD
) had tumours. Bigenic animals had significant worse survival than monogenics 
(Figure 5.1 C). 
H&E staining of tumours revealed HCC with varying degrees of differentiation in 
the majority of analysed tumours (7/10, Figure 5.1 D). Accompanying these HCCs, we 
also identified areas formed by proliferative nonmalignant hepatocytes that tended to 
group together and replace normally shaped hepatocytes, resembling dysplastic foci 
found in HCC patients (Figure 5.1 D, “Dysplasia”). All livers displayed various degrees 
of ductular proliferation, highlighted by CK19 staining (Figure 5.1 D), a feature present 
in livers of bigenic mice at birth (Zong et al., 2009). In the remaining tumours (3/10), 
CK19
+
 cells infiltrated the malignant nodules and provoked a significant distortion of 
liver architecture (Figure 5.1 D, “Atypical pattern”). In addition to hepatocytes (normal, 
dysplastic, or malignant) and CK19
+
 cells, there was an additional cell population formed 
by high-proliferative small cells, with reduced cytoplasm and oval nuclei. These cells  
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Figure 5.1 Activated Notch induces liver oncogenesis in vivo 
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Figure 5.1 (A) Schematic representation of the generation of bigenic mice over-
expressing a constitutively active form of Notch specifically in the liver (AFP-NICD). 
(B) Tumour incidence in AFP-NICD bigenic and control NICD monogenic mice. (C) 
Kaplan–Meier curves of mice survival. (D) Representative H&E images of control liver, 
a dysplastic nodule, HCC with different degrees of differentiation, HCC with atypical 
pattern (i.e., infiltration of duct-like cells with marked architectural distortion), and 
intense ductular proliferation (as observed in CK19 staining image). 
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Figure 5.2 Phenotypic characterization of Notch-induced proliferation of oval-
shaped cells 
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Figure 5.2 Representative images of immunohistochemistry of Sox9, CK19, pan-
Cytokeratin, Vimentin, and CD31 in murine tissues. Top panel shows nontumoural liver 
from monogenic mice (R26
NICD
) with positive staining for Sox9, CK19, and pan-
Cytokeratin in cholangiocytes, and CD31 in endothelial cells. Vimentin is negative in 
parenchymal cells. Bottom panels show staining for the same markers in 3 different 
tumours from Notch-activated bigenic animals (AFP-NICD) with intense proliferation of 
atypical small oval-shaped cells. These cells are typically Sox9 positive, CK19 negative, 
and pan-Cytokeratin scattered positive. 
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showed histologic features of so-called progenitor cells, exhibiting scattered staining for 
pan-Cytokeratin and progressive loss of CK19 staining (Figure 5.2). These cells lacked 
expression of either CD31 or vimentin, excluding a mesenchymal phenotype. They were 
located either forming nests within dysplastic/tumour nodules or dispersed among normal 
hepatocytes. Overall, these data indicate that long-term activation of Notch in the mouse 
liver recapitulates different stages of human hepatocarcinogenesis and results in full-
blown HCC, including histologic features associated with progenitor cell expansion. 
5.2.2 Notch-Induced Tumors Exhibit Insulin-Like Growth Factor 2 
Promoter Reactivation 
To examine the possible molecular alterations governing Notch-induced 
tumourgenesis, we performed genomic profiling of 5 tumours derived from AFP-NICD 
mice using whole-genome transcriptome arrays and compared them with 4 monogenic 
livers. Analysis of differentially expressed genes (Villanueva et al., 2012) revealed 
significant (q value < .05) up-regulation of Notch target genes such as Spp1 (37.4-
fold), Sox9 (4.4-fold), Nrarp (2.98-fold), Hes1 (2.9-fold), and Hey2 (2.8-fold) in tumours. 
In addition, genes involved in cell cycle regulation were significantly up-regulated, 
including Dnase1, Cdk1, Ccna2, Ccnd1, Ccnb2 (all > 2.5-fold up-regulated). Tumours 
showed significant down-regulation of members of the cytochrome P450 superfamily, 
which are involved in hepatic detoxification and homeostasis (e.g., Cyp2a22, Cyp2b13, 
and Cyp2b9, all > 15-fold down-regulated). As expected, gene set enrichment analysis 
identified gene sets defining oncogenic phenotypes in tumours, whereas control livers 
were markedly enriched in gene sets associated with metabolic biosynthesis (Villanueva 
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et al., 2012). Analysis of gene ontology terms found concordant results (Villanueva et al., 
2012). 
The mitogen insulin-like growth factor 2 (Igf2) was markedly induced in AFP-
NICD tumours (16.3-fold up-regulated). H19, an imprinted gene for a long noncoding 
RNA that is commonly co-regulated with Igf2, was also over-expressed (39.5-fold). 
Typically, fetal liver express Igf2 transcribed from 3 different promoters that can be 
detected using exon-specific PCR (Figure 5.3 A). Because previous reports have 
documented IGF2 overexpression and reactivation of fetal IGF2 promoters in human 
HCC (Nardone et al., 1996; Tovar et al., 2010),we tested whether this was also occurring 
in Notch-induced tumours in mice. Igf2 promoters P1–P3 were strongly induced in 
tumours (4/5) when compared with control liver, mirroring the Igf2 messenger RNA 
(mRNA) array levels (Figure 5.3 B). 
We also sought to identify candidate oncogenic partners during Notch-induced 
transformation. Hence, we profiled livers from AFP-NICD mice (n = 6) at birth 
(postnatal days 0–2)—prior to the development of HCC or dysplasia—and compared 
them with monogenic livers (n = 5). As predicted, Notch target genes were significantly 
up-regulated in bigenic new-born livers (Villanueva et al., 2012). Consistent with these 
results, the Notch pathway appeared among top canonical pathways enriched upon 
ingenuity pathway analysis (Villanueva et al., 2012). In contrast to the tumours, the 
imprinted genes Igf2 and H19 were not significantly deregulated in new-born AFP-NICD 
mice. This finding suggests that Igf2 may cooperate with activated Notch during 
malignant progression. 
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Figure 5.3 Insulin-like growth factor 2 (IGF2) promoter reactivation in Notch-
induced tumours 
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Figure 5.3 (A) Schematic representation of murine Igf2 mRNAs structure according to 
differential promoter usage events. (B) Exon specific PCR identifies Igf2 P1, P2, and P3 
promoter reactivation in Notch-induced tumours in bigenic mice (AFP-NICD), whereas 
none of the control livers evaluated (R26
NICD
 mice) showed promoter reactivation. (C) 
Promoter reactivation correlates with Igf2microarray mRNA levels. The tumour without 
promoter reactivation did not show high mRNA levels of Igf2. 
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5.2.3 Activation of the Notch Pathway Occurs Frequently in Human HCC 
We then used comparative functional genomics to determine whether Notch 
pathway activation occurs frequently in human HCC samples. For that purpose, we  
generated a 384-gene signature using differentially expressed genes between Notch-
induced tumours in AFP-NICD mice and control liver from monogenics (Villanueva et 
al., 2012). The Notch tumour signature was first tested in our cohort of human samples 
recapitulating hepatitis C virus (HCV)-associated hepatocarcinogenesis (normal liver [n = 
10], cirrhosis [n = 13], dysplastic nodules [n = 18], and full-blown HCC [n = 91] (Chiang 
et al., 2008; Wurmbach et al., 2007)) using NTP (Hoshida, 2010). Interestingly, a subset 
of cancerous tissues held a significant prediction for the signature but none of 
noncancerous tissue, which suggested that the signature was mostly capturing Notch 
activation in transformed tissues. When NTP was performed in HCCs, the Notch 
signature predicted activation of Notch in 29 out of 91 (31.8%) human HCC (Figure 5.4). 
To rule out whether the signature was capturing unspecific genomic signals of malignant 
transformation unrelated to Notch activation, we defined a separate signature—consisting 
of 276 genes—using liver tissue from new-born bigenic animals (before tumour onset). 
When applied to human HCC, even though fewer samples were predicted with this Notch 
new-born signature (18%, 17/91), they were still significantly enriched in the Notch 
tumour signature (P < .001; Figure 5.5). Interestingly, both signatures were enriched in a 
robust HCC subclass recently identified (proliferation class (Chiang et al., 2008),P 
< .001; Figure 5.5). Thus, the 386-gene Notch tumour signature identifies a subgroup of  
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Figure 5.4 Notch activation and de-regulation in human HCC 
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Figure 5.4 Prediction of the Notch signature (red in the first row) in HCCs of the HCV-
related data-set (n = 91). Each square represents data of each individual sample. One 
third of the samples (31.8%) had activation of Notch based on a significant prediction for 
the presence of the signature (false discovery rate [FDR] < 0.05, nearest template 
prediction method). Chiang et al. showed tumours with the Notch signature were 
significantly enriched in the proliferation class of our molecular classification of 
HCC (Proliferation = green). In addition, HCCs with activated Notch were significantly 
enriched in different markers of IGF pathway activation including phosphorylated (p)-
Akt, p-IGF1R, p-RPS6 (immunohistochemistry), as well as high expression levels 
of IGF2 according to data from Tovar et al. The bottom panel shows Notch Pathway 
Gene List (see Materials and Methods section for details) genes found significantly 
deregulated between Notch-activated HCC and those HCC without the signature as well 
as with normal liver (FDR < 0.05, red and blue bars in the first row, respectively). 
Deregulation magnitude is graded based on a red (over-expression) and green gradient 
(down-regulation) normalized to the median expression value in normal liver. 
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Figure 5.5 Prediction overlap between Notch tumour and new-born signatures in 
human HCC 
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Figure 5.5 Comparative analysis of predictions from the Notch tumour (384 genes) and 
new-born (276 genes) signatures. There is a significant association between them and 
also with the proliferation class of the molecular classification of HCC
4
 (Fisher exact 
test). 
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nearly one-third of human HCCs associated with HCV. 
Having captured a subset of Notch-associated human HCCs based on the 
signature generated in murine tumours, we next determined the status of potential 
downstream effectors in these samples. To do so, we first crafted a Notch gene list 
 (n = 96) by merging previously reported lists of Notch pathway genes (Higgins et al., 
2007; Kanehisa and Goto, 2000; Villanueva et al., 2012). When evaluating their 
differential expression between Notch-activated HCC (n = 29) and normal liver (n = 
10, Figure 5.4), we found a significant up-regulation of several Notch activators such as 
ligands (e.g., JAG1), α-secretases (e.g., ADAM17), effectors (e.g., MAML1, NOV) and 
target genes (eg,SOX9, SPP1, HEY1). Pathway inhibitor ITCH was significantly down-
regulated. In accordance with data from murine tumours, Notch-activated human HCCs 
were significantly enriched for high levels of IGF2 expression (Fisher exact test, P 
= .003; Figure 5.4), an alteration we previously found to be associated with fetal 
promoter reactivation (Tovar et al., 2010). In addition, these tumours exhibited activation 
of the IGF, AKT, and MTOR pathways as determined by phospho(p)-IGF-1R, p-Akt, and 
p-RPS6 IHC staining (Figure 5.4). To address possible mechanisms underlying Notch 
activation in humans, we integrated gene expression data with DNA copy number 
changes in the same cohort for Notch pathway genes. We failed to find high-level 
amplifications affecting any putative Notch gene, but there were DNA gains affecting 
the HEY1 locus (chromosome 8).HEY1 is a Notch target gene significantly up-regulated 
in HCCs with the Notch signature compared with normal tissue and tumours without the 
signature, mostly in those samples with DNA gains (Figure 5.4 and Figure 5.6). 
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Figure 5.6 HEY1 alterations in human HCC 
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Figure 5.6   (Top left) HEY1 expression in normal (NOR, n = 10), cirrhotic (CIR, n = 13), 
low-grade dysplastic nodule (LGDN, n = 10), high-grade dysplastic nodule (HGDN, n = 
8), and hepatitis C virus (HCV)-associated HCC (HCC, n = 91). (Top right) Copy 
number alterations in HCV-associated HCCs (n = 104) in HEY1 locus; dashed 
lines correspond to maximum and minimum copy number values in paired cirrhotic 
tissue. (Bottom) Correlation between HEY1 gene expression data and HEY1 locus copy 
number alterations. 
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We further tested the performance of the signature on an additional set of 144 
HCCs from different etiologies including also hepatitis B infection and alcohol-induced 
HCC (Villanueva et al., 2011). Consistent with the results obtained using the HCV set, 
29.2% (42/144) of these tumours exhibited the Notch signature. To assess the validity of  
this signature in biologic samples, we performed IHC for the Notch target SOX9 in a 
subset of HCC with (n = 27) and without (n = 24) the Notch signature. Nuclear staining 
of SOX9 (Figure 5.7 A) was more prevalent in HCCs with the Notch signature than 
without (19/27 vs 6/24, respectively, P = .001), and mRNA levels of SOX9 were 
associated with both SOX9 nuclear staining and the Notch signature prediction (P 
< .001, Figure 5.7 B). 
SOX9 has been shown to maintain pancreatic progenitors, and it has been 
proposed as a marker of progenitor cells with bipotentiality in the adult liver (Furuyama 
et al., 2011; Seymour et al., 2007). An emerging role of SOX9 in cancer promotion and 
metastasis seeding has also been suggested (Guo et al., 2012).
 
SOX9 was highly up-
regulated in Notch-activated HCC (10.6-fold compared with normal liver, Figure 5.4). 
Additionally, we observed increased SOX9 levels in an aggressive microRNA-based 
molecular subclass of HCC (C3 subclass (Toffanin et al., 2011)) and identified miR-30 as 
a candidate regulator of SOX9 (Figure 5.8). 
Previous studies have identified activating NOTCH1 mutations in solid tumours 
(Westhoff et al., 2009). Hence, we sought to estimate their prevalence in our data set and 
searched for the presence of mutations at hotspot exons 26, 27, and 34 of 
the NOTCH1 gene using direct sequencing in 50 human HCCs from our HCV-related  
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Figure 5.7 Deregulation of the Notch target gene SOX9 in HCC 
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Figure 5.7   (A) Representative images of nuclear SOX9 staining. Top panels show 
SOX9 staining in mice: stained bile duct cells in livers from control monogenic mice 
(upper left) and stained hepatocytes and cholangiocytes in murine tumours (upper 
right). Bottom panels show human HCC samples with negative (bottom left) and positive 
(bottom right) nuclear staining. (B) Boxplots of SOX9 messenger RNA levels from HCC 
samples (n = 51) with and without the Notch signature (left) or SOX9 nuclear staining 
(right). 
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data set. Two samples showed nonsynonymous mutations (4%), indicating that activating 
mutations in hotspots of theNOTCH1 gene do not account for pathway deregulation in 
most HCC cases. 
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Figure 5.8 SOX9 regulation by miR-30 in HCC 
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Figure 5.8   (A) Expression of SOX9 in HCC (n = 89, hepatitis C virus-related data set) 
according to our previously described microRNA subclasses by Wurmbach et al., which 
overlaps with our mRNA-based classification. (B) In silico prediction shows sequence 
complementary between miR-30 members and SOX9 3′ untranslated region (UTR) 
(TargetScan software). (C) Dot plot representing the inverse correlation 
between SOX9 mRNA levels and miR-30a.3p in HCCs (n = 89). (D) Decrease in 
luciferase activity from a SOX9-3′UTR-containing dual firefly/Renilla luciferase reporter 
following transfection of miR-30a in Huh7 cells. 
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5.2.4  The Notch Signature Coclusters Within the Proliferation Class and 
Predicts Response to Selective Notch Inhibition 
To understand better the predictive performance of the Notch 384-gene signature 
in human HCC, we further evaluated 5 publicly available HCC data sets, including a total  
of 407 samples using the NTP method (Villanueva et al., 2012). We also integrated data 
of Notch predictions with our previously described molecular classification of HCC 
(Chiang et al., 2008). As a whole, between 20% and 37% of samples in each HCC data 
set showed the presence of the Notch signature (Figure 5.9 A). Of note, when we focused 
on those data sets with higher number of significant predictions based on a false 
discovery rate < 0.05, the prediction rate for Notch ranged between 32% and 37%, very 
close to that of our own cohorts (∼30%). In most data sets, there was a significant 
correlation between the Notch signature and our previously defined proliferation class 
(Chiang et al., 2008), a class characterized by genomic signals related to cell cycle 
progression and proliferation. Thereafter, we tested the similarity between the Notch 
signature and signatures previously reported to confer aggressive clinical behaviour in 
HCC using Cramer's V coefficient (Villanueva et al., 2011). The Notch signature 
coclustered with a group including the proliferation class (Chiang et al., 2008), a 
CK19
+
 progenitor-derived HCC signature generated in rats (Andersen et al., 2010), a 
cholangiocarcinoma-like gene expression trait described in HCC (Woo et al., 2010), and 
a prognostic transforming growth factor-β signature generated in mouse hepatocytes 
(Coulouarn et al., 2008) (Figure 5.9 B). The Notch signature was not correlated with  
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Figure 5.9 Signature-based activation of Notch across HCC data sets 
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Figure 5.9   (A) Performance of the Notch signature across HCC data sets. Top rows in 
each data-set represent Notch predictions, and bottom rows show our molecular 
classification of HCC
 
(Chiang et al., 2008) (Proliferation = green) for each sample. In all 
except 1 data set (HCC-Izuka), tumours with Notch activation are enriched in patients of 
the Proliferation class. (B) Heatmap of Cramer's V coefficient showing correlation 
between the Notch signature and other previously reported signatures that predict clinical 
aggressive behaviour (from Villanueva et al., 2001 and Hoshida et al., 2009). Briefly, 
Cramer's V statistic values range from 0 to 1, being 0.36–0.49 substantially correlated, > 
0.5 strongly correlated, and 1 identical. 
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clinical outcome in these patients, which points toward its limited role as a prognostic 
biomarker in HCC (Hoshida et al., 2009). 
To evaluate further the Notch 384-gene signature and determine whether it 
predicts sensitivity to Notch pathway inhibitors, we applied this signature to a large panel 
of cancer cell lines (n = 318) whose expression data are available online (caBIG). We 
found that the signature captured Notch activation mainly in cells derived from solid  
Tumours, as opposed to hematologic malignancies, and liver cancer cell lines showed 
varied profiles (Figure 5.10 A). Next, we focused on the Notch signature prediction in a 
panel of 21 liver cancer cell lines (CCLE (Barretina et al., 2012),
 
Figure 5.10 B) and 
selected 3 lines with the Notch signature (SNU423, SNU475, and SNU449) and 2 
without (HepG2 and Huh7) for further analysis. When incubated with 2 μmol/L 
Compound E, a GSI that inhibits ligand-dependent Notch signalling, SNU423 and 
SNU475 showed significant decrease in cell viability, whereas HepG2 and Huh7 
remained irresponsive (P = .002, Figure 5.10 C). To obtain a more specific inhibition of 
the pathway, we transfected SNU449, SNU475, and HepG2 cells with a construct 
containing a dominant negative form of the transcriptional coactivator of Notch, MAML1 
(DN-MAML-GFP). SNU449 and SNU475 (Notch signature positive) showed decreased 
proliferation upon DN-MAML-GFP infection in comparison with GFP-only cells (P < 
.03, Figure 4.10 D). In contrast, HepG2 (Notch signature negative) showed an increase in 
proliferation (P = .036, Figure 5.10 D). 
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Figure 5.10 Notch signature predicts response to Notch inhibition in vitro 
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Figure 5.10  (A) Prediction of the Notch signature in 318 cancer cell lines from the 
Cancer Biomedical Informatics Grid, caBIG National Cancer Institute (Bethesda, MD) 
(dark green: solid tumours’ cell lines; light green: hematologic malignancies' cell lines). 
(B) Notch signature prediction in 21 liver cancer cell lines (Broad-Novartis Cancer Cell 
Line Encyclopedia, Barretina et al.).  Cell lines used in further analysis are highlighted 
in bold. (C) Cell viability upon 5-day incubation with a γ-secretase inhibitor. Decrease in 
viability was restricted to cells harbouring the Notch signature; standard deviation is 
shown. (D) Representative images of phospho-histone H3 (pHH3) staining in DN-
MAML-GFP and GFP-only (control) transfected cells; white arrowheads highlight 
transfected proliferating cells (GFP
+
 and pHH3
+
). Quantification of cell proliferation was 
evaluated by enumerating pHH3
+
 GFP
+
 cells as a percentage of total GFP
+ 
cells in liver 
cancer cell lines 48 hours post infection; standard deviation is shown. 
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5.3 Discussion 
In this study, we have undertaken a comprehensive and integrative approach to 
explore the role of Notch signalling in liver cancer pathogenesis. We have found that 
Notch signalling promotes liver carcinogenesis in a genetically engineered mouse model 
and that this pathway is activated in one third of human HCCs. Specifically, our studies 
demonstrate that (1) liver-specific Notch activation in mice recapitulates features of 
human hepatocarcinogenesis, including dysplasia and HCC; (2) several genes involved in 
the Notch signalling cascade are deregulated in HCC, particularly SOX9; (3) Notch1 is a 
bona fide oncogene in experimental liver cancer; (4) Notch and IGF signalling are 
frequently coactivated in experimental and human HCCs, and Igf2 induction occurs via 
reactivation of silenced Igf2 promoters; (5) a 384-gene signature obtained from Notch-
induced tumours is able to recognize pathway activation in approximately 30% of human 
HCCs from different etiologies; (6) inhibiting Notch signalling in liver cancer cells lines 
that harboured the Notch signature, but not those that lacked it, resulted in growth 
inhibition. Taken together, these data suggest that activation of Notch signalling is pivotal 
in liver oncogenesis. 
The role of the Notch cascade in solid tumours is controversial (Ranganathan et 
al., 2011),
 
and, despite strong data indicating that Notch activation facilitates tumour 
progression in the liver (Lim et al., 2011; Liu et al., 2012), some reports suggest the 
opposite (Qi et al., 2003; Viatour et al., 2011; Wang et al., 2009),  a discrepancy that may 
be due to the high context dependency of the Notch cascade (Ranganathan et al., 
2011).
 
 Ours is the first study to use a genetically engineered mouse model to test the 
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tumorigenicity impact of liver-specific Notch activation in vivo. In our model, HCCs 
arose with a latency of greater than 6 months, suggesting that additional hits may be 
needed in addition to Notch deregulation to achieve cell transformation. In this regard, 
we found strong up-regulation of Igf2 in Notch-derived tumours, raising the possibility 
that Igf2 acts as an oncogenic partner of Notch in this setting. Reactivation of Igf2 fetal 
promoters and their tight correlation with mRNA levels lends credence to such a 
cooperative pathogenic role because both promoter reactivation and IGF2 up-regulation 
are well-recognized features of human HCC (Nardone et al., 1996; Tovar et al., 
2010). Whether there is a functional cross talk between both cascades in HCC needs 
further evidence. Previous reports suggested a cooperative oncogenic role between Notch 
and other pathways such as RAS (Weijzen et al., 2002). 
We undertook a comparative functional genomics (Lee et al., 2004) approach to 
connect molecular pathogenic features of human cancer to the mouse model by 
integrating high-density genomic data. This approach has previously been used in HCC 
(Lee et al., 2004), which resulted in the identification of best-fit mouse models to model 
human HCC. In line with this concept, we aimed to translate detection of aberrant Notch 
activation in rodent HCC to humans by identifying common transcriptome deregulation 
patterns in murine Notch-activated tumours and human HCC. To this end, we generated a 
384-gene signature of Notch-activated HCC from mice and determined its predictive 
performance in 642 human HCC samples. Overall, 30%–35% of HCCs were confidently 
predicted to harbour the signature, regardless of etiology and disease stage. Strikingly, 
tumours with the signature were significantly enriched in the “Proliferation class” of our 
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previously described molecular classification (Chiang et al., 2008)  and showed 
deregulation of several Notch pathway genes such as HEY1, which has been recently 
proposed as an oncogene in HCC (Jia et al., 2011). Recent data suggest that this class is 
heterogeneous, capturing different genomic signals related to transforming growth factor-
β (Hoshida et al., 2009), MET (Kaposi-Novak et al., 2006), IGF (Chiang et al., 2008; 
Tovar et al., 2010), and progenitor-derived HCC (Lee et al., 2006). 
Detailed pathologic examination of Notch-induced HCC identified 3 major cell 
populations: (1) “proliferative” duct-like cells, which were positive for CK19; (2) 
hepatocyte-like cells, which were negative for CK19, including normal, dysplastic, and 
malignant hepatocytes; and (3) atypical small oval-shaped cells, which formed nests 
within tumours that were CK19 negative but positive for scattered pan-Cytokeratin 
staining. All Notch-induced tumours showed various degrees of nuclear staining for the 
Notch target gene Sox9, and SOX9overexpression was frequently observed in human 
HCCs, particularly those tumours bearing the Notch signature. A recent study (Furuyama 
et al., 2011) suggests that Sox9 marks a pluripotent population within the liver, and, thus, 
it is possible that Notch acts during hepatocarcinogenesis by expanding a pre-existing 
progenitor-like cell or conferring progenitor-like properties to differentiated cells during 
hepatocarcinogenesis. 
The success of targeted therapies that block oncogene addiction loops, such as 
vemurafenib (Chapman et al., 2011) in mutant BRAF melanomas or crizotinib in lung 
cancer patients with ALK rearrangements (Kwak et al., 2010), underscores the 
importance of identifying molecular drivers of cancer. At present, HCC lacks any known 
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oncogene addiction loop amenable for selective targeting. Recent failures in phase 3 trials 
with systemic agents (e.g., sunitinib negative in first line and brivanib negative in first 
and second line) highlight the need for new therapeutic targets and a change in trial 
design to routinely include enrichment strategies based on molecular markers of 
response, and the Notch signature fulfils both criteria. Similarly to other molecular 
biomarkers of response in oncology (e.g., ALK rearrangements in lung cancer), lack of 
prognosis performance of the Notch signature does not diminish its potential role as a 
therapeutic biomarker. We provide evidence of differential response to selective Notch 
inhibition depending on the presence or absence of a Notch signature, both with a 
pharmacologic inhibitor (GSI) and a specific molecular inhibitor (dominant negative 
MAML) of Notch signalling. This finding raises the possibility that the estimated 30% of 
HCCs exhibiting Notch pathway activation could be responsive to Notch inhibition. 
Prospective trials, ideally including populations enriched with biomarkers of Notch 
activation, will be necessary to address this issue. Of note, interrogation of a cohort of 
318 cancer cell lines for the presence of the 384-gene signature predicted Notch 
activation only in cells derived from solid tumours. The presence of differential genomic 
traits between Notch-induced solid tumours and hematologic malignancies might be 
expected with such a context-dependent pleiotropic pathway. 
In summary, this study provides evidence that the Notch pathway is involved in 
the pathogenesis of HCC, with 30%–35% of tumours exhibiting pathway activation 
according to a novel gene signature across different data-sets. Overall, our findings 
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indicate that Notch may be an appealing target for new drug development initiatives in 
HCC. 
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6 MATERIALS AND METHODS 
Mouse Studies 
  Mice were maintained in a pathogen-free environment.  AFP
Cre
, R26
YFP
, 
RBP-Jκ, and R26
NICD
 strains have previously been described (Han et al., 2002; 
Kellendonk et al., 2000; Murtaugh et al., 2003; Srinivas et al., 2001). To generate 
an ADC response, animals were given 0.1% wt/wt DDC (3,5-diethoxycarbonyl-1,4-
dihydrocollidine; Sigma-Aldrich) in PMI mouse diet #5015 (Harlan Teklad) for 1-6 
weeks as described (Wang et al., 2003a). Choline deficient + ethionine diet (CDE) 
was administered for 3 weeks with choline-deficient pellets (MP Biomedicals) ad-
libitum and fresh drinking water with 0.15% ethionine (Sigma-Aldrich) prepared 
every 2-3 days as described (Carpentier et al., 2011). α-naphthylisothiocyanate 
pellets (ANIT) (Dyets) were administered for 2 weeks (Faa et al., 1998). For 
recovery studies, animals were switched back to normal show for 2-5 weeks before 
assessing the livers. CCl4 intoxication was conducted as described (Malato et al., 
2011) with injections twice weekly at a dose of 0.5ul/g of body weight and diluted 
in corn oil (Sigma-Aldrich). Partial hepatectomy (PHx) and bile duct ligation 
(BDL) were performed as described (Chu AS, 2011; Greenbaum et al., 1995).All 
studies were conducted in accordance with the policies of the National Institutes of 
Health and the University of Pennsylvania Institutional Animal Care and Use 
Committee guidelines. In vivo BrdU labelling was performed by adding BrdU 
(Sigma, Lot#040M1344) to the drinking water at a concentration of 0.5 mg/ml 
coinciding with 1-2 weeks of DDC treatment. 
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Immunostaining and quantification 
  Antibody staining was performed as previously described (Zong et al., 2009) 
and listed in Table 1. The percentage of marker-positive cells and binucleated 
biliary cells was determined by taking representative images and directly counting 
cell number. Samples were obtained from at least three animals; cell enumerations 
for each experiment are listed in the text or Figure legends. Human explant liver 
tissues were obtained from tissue banks at the Children's Hospital of Philadelphia or 
Mount Sinai School of Medicine, collected with IRB approval. 
Antibody Species Source Catalogue # Dilution 
Cytokeratin19 Rabbit D. Melton NA 1:1000 
GFP Chicken Abcam ab13970 1:500 
GFP Goat Abcam ab6673 1:500 
A6 Rat V. Factor NA 1:100 
Hnf4α Goat Santa Cruz SC-6556 1:250 
Hnf4α Rabbit Santa Cruz SC-8987 1:250, TSA 
Ki-67 Mouse BD 561165 1:100 
1D11 Rat Novus Biologicals NBP1-18963 1:100 
4E8 Rat Novus Biologicals NBP1-18971 1:100 
2F3 Rat Novus Biologicals NBP1-18964 1:100 
3C7 Rat Novus Biologicals NBP1-18970 1:100 
TROP2 Mouse R&D AF1122 1:100 
Ki-67 Rabbit Thermo Scientific MA1-90584 1:100 
Hes1 Rabbit In-house NA 1:1000, TSA 
Hnf1β Goat Santa Cruz SC-7411 1:250, TSA 
A6 Rat V. Factor NA 1:100 
Par6 Rabbit Santa Cruz sc67393 1:250, TSA 
PKCζ Rabbit Santa Cruz Sc-216 1:250, TSA 
Osteopontin Goat R&D AF808 1:500 
Sox9 Rabbit Millipore ab5535 1:1000, TSA 
Ac-tubulin Mouse Sigma T6793 1:200 
EpCAM Rat BD 552370 1:500 
Table 1. List of Antibodies 
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Quantitative PCR 
 Total RNA was extracted from FACS sorted cells using the RNeasy Mini Kit 
(Qiagen) and 30-50 ng was used to synthesize cDNA using the iScript cDNA 
Synthesis Kit (BioRad, 170-8890). Quantitative PCR was performed with 
SsoAdvanced™ SYBR® Green Supermix (Bio-Rad), 312 nM of Primer Mix (IDT) 
and cDNA template diluted 10-fold.  Fold enrichment was determined using the 
difference of Ct method with values normalized to GAPDH.  Primer sequences are 
listed in Table.  
Gene Forward Reverse  
GAPDH ATGTTCCAGTATGACTCCACTCACG GAAGACACCAGTAGACTCCACACA 
CK19 GACCTAGCCAAGATCCTGAGT TCAGCTCCTCAATCCGAGCA 
EpCAM GCGGCTCAGAGAGACTGT CCAAGCATTTAGACGCCAGTTT 
Sox9 ACTCTGGGCAAGCTCTGGAG CGAAGGGTCTCTTCTCGCTCT 
HNF1β CCCAGCAATCTCAGAACCTC AGGCTGCTAGCCACACTGTT 
Hes1 AAAGCCTATCATGGAGAAGAGGCG GGAATGCCGGGAGCTATCTTTCTT 
AFP CCTCCCAGTGCGTGACGGAGAA CACTTCCTCCTCGGTGGCTTCC 
 
Table 2. List of Primers 
Viral infections 
 Replication incompetent AAV viruses were obtained from the Penn Vector Core.  
AAV8-TBG-Cre carries Cre recombinase under the regulatory control of the hepatocyte-
specific thyroid binding globulin (TBG) promoter, while AAV8-CMV-Cre carries Cre 
recombinase under the regulatory control of the ubiquitous CMV promoter. In vivo cell 
labelling with AAV8-TBG-Cre and AAV8-CMV-Cre was achieved by giving mice of the 
appropriate genetic background either 2.5 X 10
11
 viral particles (regular dose) diluted in 
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sterile 1X PBS. For activating Notch signalling in differentiated hepatocytes, AAV-TBG-
Cre was administered to mice via retro-orbital injection at a dose of 1x10
11
 GC/animal (or 
1x10
10
 GC/animal diluted in PBS for low dose experiments).   
Tamoxifen administration 
 KRT19-CreER transgenes was achieved by giving mice 40 mg of tamoxifen 
(TM) over 5 doses. For labelling ADCs, KRT19-CreER; R26
YFP
 mice were given 3-
5 doses of 8 mg/dose TM during the second week of DDC treatment. All studies 
were conducted in accordance with the policies of the National Institutes of Health 
and the University of Pennsylvania Institutional Animal Care and Use Committee 
guidelines. 
Liver cell preparation 
 Livers of normal and DDC-treated mice were perfused initially with 1X 
HBBS solution followed by perfusion media (1X HBSS, 0.1 M CaCl2) containing 
5mg/ml Liberase (Fisher Scientific). The digested liver and cells were further 
agitated by pipetting and collected through a 70-µm cell strainer for FACS 
analysis/collection. 
Flow cytometry staining 
 Cells were counted and blocked, followed by staining with EpCAM and IgG 
isotype control antibodies. After washing, cells were passed through a 40-µm cell 
strainer and analysed/collected by FACS Aria (Becton Dickinson) using DAPI to 
exclude dead cells.   
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